المؤلفون: E. Kanner V., M. Maksimov L., I. Kanner D., N. Lapkin M., A. Gorelov V., Е. Каннер В., М. Максимов Л., И. Каннер Д., Н. Лапкин М., А. Горелов В.

المصدر: Meditsinskiy sovet = Medical Council; № 1 (2022); 115-120 ; Медицинский Совет; № 1 (2022); 115-120 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: infant colic, gut, functional gastrointestinal disorders, microbiome, probiotics, младенческая колика, кишечник, функциональные нарушения желудочно-кишечного тракта, микробиом, пробиотики

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6692/6037; Wessel M.A., Cobb J.C., Jackson E.B., Harris G.S. Jr., Detwiller A.C. Paroxysmal fussing in infancy, sometimes called colic. Pediatrics. 1954;14(5):421–435. Available at: https://pubmed.ncbi.nlm.nih.gov/13214956.; Hizli S., Can D., Kiliç I., Örün E., Tunç T., Özkan H. Diagnosis and Treatment Approaches in Infantile Colic (IC): Results of a Survey Among Paediatricians in Turkey. Front Pediatr. 2021;9:779997. https://doi.org/10.3389/fped.2021.779997.; Steutel N.F., Benninga M.A., Langendam M.W., de Kruijff I., Tabbers M.M. Reporting outcome measures in trials of infant colic. J Pediatr Gastroenterol Nutr. 2014;59(3):341–346. https://doi.org/10.1097/MPG.0000000000000412.; van Tilburg M.A.L., Hyman P.E., Walker L., Rouster A., Palsson O.S., Kim S.M., Whitehead W. Prevalence of functional gastrointestinal disorders in infants and toddlers. J Pediatr. 2015;166(3):684–689. https://doi.org/10.1016/j.jpeds.2014.11.039.; Drossman D.A. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130(5):1377–1390. https://doi.org/10.1053/j.gastro.2006.03.008.; van Tilburg M.A.L., Rouster A., Silver D., Pellegrini G., Gao J., Hyman P.E. Development and validation of a Rome III functional gastrointestinal disorders questionnaire for infants and toddlers. J Pediatr Gastroenterol Nutr. 2016;62(3):384–386. https://doi.org/10.1097/MPG.0000000000000962.; Baaleman D.F., Di Lorenzo C., Benninga M.A., Saps M. The effects of the Rome IV criteria on pediatric gastrointestinal practice. Curr Gastroenterol. Rep. 2020;22:21. https://doi.org/10.1007/s11894-020-00760-8.; Palsson O.S., Whitehead W.E., van Tilburg M.A.L., Chang L., Chey W., Crowell M.D. et al. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology. 2016;150(6):1481–1491. https://doi.org/10.1053/j.gastro.2016.02.014.; Morris S., James-Roberts I.S., Sleep J., Gillham P. Economic evaluation of strategies for managing infant crying and sleep problems. Arch Dis Child. 2001;84(1):15–19. https://doi.org/10.1136/adc.84.1.15.; Lucassen P.L., Assendelft W.J. Systematic review of treatments for infant colic. Pediatrics. 2001;108(4):1047–1048. https://doi.org/10.1542/peds.108.4.1047.; Wolke D., Bilgin A., Samara M. Systematic review and meta-analysis: fussing and crying durations and prevalence of colic in infants. J Pediatr. 2017;185:55–61.e4. https://doi.org/10.1016/j.jpeds.2017.02.020.; Johnson J.D., Cocker K., Chang E. Infantile Colic: Recognition and Treatment. Am Fam Physician. 2015;92(7):577–582. Available at: https://pubmed.ncbi.nlm.nih.gov/26447441.; Daelemans S., Peeters L., Hauser B., Vandenplas Y. Recent advances in understanding and managing infantile colic. F1000Res. 2018;7:F1000 Faculty Rev-1426. https://doi.org/10.12688/f1000research.14940.1.; Gelfand A.A. Episodic syndromes of childhood associated with migraine. Curr Opin Neurol. 2018;31(3):281–285. https://doi.org/10.1097/WCO.0000000000000558.; Tanaka M., Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. Allergol Int. 2017;66(4):515–522. https://doi.org/10.1016/j.alit.2017.07.010.; Vandenplas Y., Abkari A., Bellaiche M., Benninga M., Chouraqui J.P., Çokura F. et al. Prevalence and health outcomes of functional gastrointestinal symptoms in infants from birth to 12 months of age. J Pediatr Gastroenterol Nutr. 2015;61(5):531–537. https://doi.org/10.1097/MPG.0000000000000949.; Steutel N.F., Zeevenhooven J., Scarpato E., Vandenplas Y., Tabbers M.M., Staiano A. et al. Prevalence of functional gastrointestinal disorders in european infants and toddlers. J Pediatr. 2020;221:107–114. https://doi.org/10.1016/j.jpeds.2020.02.076.; Muhardi L., Aw M.M., Hasosah M., Ng R.T., Chong S.Y., Hegar B. et al. A Narrative Review on the Update in the Prevalence of Infantile Colic, Regurgitation, and Constipation in Young Children: Implications of the ROME IV Criteria. Front. Pediatr. 2022;9:778747. https://doi.org/10.3389/fped.2021.778747.; Shamir R., St James-Roberts I., Di Lorenzo C., Burns A.J., Thapar N., Indrio F. et al. Infant crying, colic, and gastrointestinal discomfort in early childhood: a review of the evidence and most plausible mechanisms. J Pediatr Gastroenterol Nutr. 2013;57(1 Suppl.):S1–S45. https://doi.org/10.1097/MPG.0b013e3182a154ff.; Nation M.L., Dunne E.M., Joseph S.J., Mensah F.K., Sung V., Satzke C., Tang M.L.K. Impact of Lactobacillus reuteri colonization on gut microbiota, inflammation, and crying time in infant colic. Sci Rep. 2017;7(1):15047. https://doi.org/10.1038/s41598-017-15404-7.; Pärtty A., Kalliomäki M., Salminen S., Isolauri E. Infantile Colic Is Associated With Low-grade Systemic Inflammation. J Pediatr Gastroenterol Nutr. 2017;64(5):691–695. https://doi.org/10.1097/MPG.0000000000001340.; Eutamène H., Garcia-Rodenas C.L., Yvon S., d’Aldebert E., Foata F., Berger B. et al. Luminal contents from the gut of colicky infants induce visceral hypersensitivity in mice. Neurogastroenterol Motil. 2017;29(4):e12994. https://doi.org/10.1111/nmo.12994.; de Weerth C., Fuentes S., de Vos W.M. Crying in infants: on the possible role of intestinal microbiota in the development of colic. Gut Microbes. 2013;4(5):416–421. https://doi.org/10.4161/gmic.26041.; Pärtty A., Kalliomäki M., Endo A., Salminen S., Isolauri E. Compositional development of Bifidobacterium and Lactobacillus microbiota is linked with crying and fussing in early infancy. PLoS ONE. 2012;7(3):e32495. https://doi.org/10.1371/journal.pone.0032495.; Savino F., Cordisco L., Tarasco V., Calabrese R., Palumeri E., Matteuzzi D. Molecular identification of coliform bacteria from colicky breastfed infants. Acta Paediatr. 2009;98(10):1582–1588. https://doi.org/10.1111/j.1651-2227.2009.01419.x.; Halpern M.D., Denning P.W. The role of intestinal epithelial barrier function in the development of NEC. Tissue Barriers. 2015;3(1–2):e1000707. https://doi.org/10.1080/21688370.2014.1000707.; Vandenplas Y., Benninga M., Broekaert I., Falconer J., Gottrand F., Guarino A. et al. Functional gastro-intestinal disorder algorithms focus on early recognition, parental reassurance and nutritional strategies. Acta Paediatr. 2016;105(3):244–252. Erratum in: Acta Paediatr. 2016;105(8):984. https://doi.org/10.1111/apa.13270.; Karakan T., Ozkul C., Küpeli Akkol E., Bilici S., Sobarzo-Sánchez E., Capasso R. Gut-Brain-Microbiota Axis: Antibiotics and Functional Gastrointestinal Disorders. Nutrients. 2021;13(2):389. https://doi.org/10.3390/nu13020389.; Zeevenhooven J., Browne P.D., L’Hoir M.P., de Weerth C., Benninga M.A. Infant colic: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2018;15:479–496. https://doi.org/10.1038/s41575-018-0008-7.; McFarland L.V. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: A systematic review. BMJ Open. 2014;4:005047. https://doi.org/10.1136/bmjopen-2014-005047.; Mu Q., Tavella V.J., Luo X.M. Role of Lactobacillus reuteri in Human Health and Diseases. Front. Microbiol. 2018;9:757. https://doi.org/10.3389/fmicb.2018.00757.; Binda S., Hill C., Johansen E., Obis D., Pot B., Sanders M.E., Tremblay A., Ouwehand A.C. Criteria to Qualify Microorganisms as “Probiotic” in Foods and Dietary Supplements. Front Microbiol. 2020;11:1662. https://doi.org/10.3389/fmicb.2020.01662.; Sanders M.E., Guarner F., Guerrant R., Holt P.R., Quigley E.M.M., Sartor R.B. et al. An update on the use and investigation of probiotics in health and disease. Gut. 2013;62:787–796. https://doi.org/10.1136/gutjnl-2012-302504.; Kubota M., Ito K., Tomimoto K., Kanazaki M., Tsukiyama K., Kubota A. et al. Lactobacillus reuteri DSM 17938 and Magnesium Oxide in Children with Functional Chronic Constipation: A Double-Blind and Randomized Clinical Trial. Nutrients. 2020;12:225. https://doi.org/10.3390/nu12010225.; Trivić I., Niseteo T., Jadrešin O., Hojsak I. Use of probiotics in the treatment of functional abdominal pain in children – systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;180:339–351. https://doi.org/10.1007/s00431-020-03809-y.; Li L., Fang Z., Liu X., Hu W., Lu W., Lee Y.-K. et al. Lactobacillus reuteri attenuated allergic inflammation induced by HDM in the mouse and modulated gut microbes. PLoS ONE. 2020;15:e0231865. https://doi.org/10.1371/journal.pone.0231865.; Szajewska H., Guarino A., Hojsak I., Indrio F., Kolacek S., Orel R. et al. Use of Probiotics for the Management of Acute Gastroenteritis in Children: An Update. J Pediatr Gastroenterol Nutr. 2020;71(2):261–269. https://doi.org/10.1097/MPG.0000000000002751.; Simonson J., Haglund K., Weber E., Fial A., Hanson L. Probiotics for the Management of Infantile Colic: A Systematic Review. MCN Am J Matern Child Nurs. 2021;46:88–96. https://doi.org/10.1097/NMC.0000000000000691.; Veiga P., Suez J., Derrien M., Elinav E. Moving from probiotics to precision probiotics. Nat Microbiol. 2020;5:878–880. https://doi.org/10.1038/s41564-020-0721-1.; Tolnai E., Fauszt P., Fidler G., Pesti-Asboth G., Szilagyi E., Stagel A. et al. Nutraceuticals Induced Changes in the Broiler Gastrointestinal Tract Microbiota. mSystems. 2021;6(2):e01124–20. https://doi.org/10.1128/mSystems.01124-20.; Marco M.L., Sanders M.E., Gänzle M., Arrieta M.C., Cotter P.D., De Vuyst E. et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods. Nat Rev Gastroenterol Hepatol. 2021;18:196–208. https://doi.org/10.1038/s41575-020-00390-5.; Saviano A., Brigida M., Migneco A., Gunawardena G., Zanza C., Candelli M. et al. Lactobacillus Reuteri DSM 17938 (Limosilactobacillus reuteri) in Diarrhea and Constipation: Two Sides of the Same Coin? Medicina. 2021;57(7):643. https://doi.org/10.3390/medicina57070643.; West C.L., Stanisz A.M., Mao Y.-K., Champagne-Jorgensen K., Bienenstock J., Kunze W.A. Microvesicles from Lactobacillus reuteri (DSM-17938) completely reproduce modulation of gut motility by bacteria in mice. PLoS ONE. 2020;15:e0225481. https://doi.org/10.1371/journal.pone.0225481.; Sanders M.E., Merenstein D.J., Reid G., Gibson G.R., Rastall R.A. Probiotics and prebiotics in intestinal health and disease: From biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019;16:605–616. doi: https://doi.org/10.1038/s41575-019-0173-3.; Wadhwa A., Kesavelu D., Kumar K., Chatterjee P., Jog P., Gopalan S. et al. Role of Lactobacillus reuteri DSM 17938 on Crying Time Reduction in Infantile Colic and Its Impact on Maternal Depression: A Real-Life Clinic-Based Study. Clin Pract. 2022;12:37–45. https://doi.org/10.3390/clinpract12010005.; Savino F., Pelle E., Palumeri E., Oggero R., Miniero R. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: A prospective randomized study. Pediatrics. 2007;119:e124–e130. https://doi.org/10.1542/peds.2006-1222.; Szajewska H., Dryl R. Probiotics for the Management of Infantile Colic. J Pediatr Gastroenterol Nutr. 2016;63(1 Suppl.):S22–S24. Available at: https://pubmed.ncbi.nlm.nih.gov/27380594.; Savino F., Cordisco L., Tarasco V., Palumeri E., Calabrese R., Oggero R., Roos S., Matteuzzi D. Lactobacillus reuteri DSM 17938 in infantile colic: A randomized, double-blind, placebo-controlled trial. Pediatrics. 2010;126:e526–e533. https://doi.org/10.1542/peds.2010-0433.; Sung V., D’Amico F., Cabana M.D., Chau K., Koren G., Savino F. et al. Lactobacillus reuteri to treat infant colic: A meta-analysis. Pediatrics. 2018;141:e20171811. https://doi.org/10.1542/peds.2017-1811.; Mai T., Fatheree N.Y., Gleason W., Liu Y., Rhoads J.M. Infantile Colic: New Insights into an Old Problem. Gastroenterol Clin North Am. 2018;47(4):829–844. https://doi.org/10.1016/j.gtc.2018.07.008.; https://www.med-sovet.pro/jour/article/view/6692

الاتاحة: https://www.med-sovet.pro/jour/article/view/6692
https://doi.org/10.21518/2079-701X-2022-16-1-115-120

المؤلفون: N. Lazareva B., M. Maximov L., I. Kukes V., Н. Лазарева Б., М. Максимов Л., И. Кукес В.

المصدر: Meditsinskiy sovet = Medical Council; № 12 (2021); 181-191 ; Медицинский Совет; № 12 (2021); 181-191 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: mucolytics, erdosteine, inflammatory airway diseases, COPD, ARI, inflammation, муколитики, эрдостеин, воспалительные заболевания дыхательных путей, ХОБЛ, ОРВИ, воспаление

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6347/5746; Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007;52(9):1176–1193; discussion 1193–1197. Available at: https://pubmed.ncbi.nlm.nih.gov/17716385.; Лазарева Н.Б., Ермакова В.А. Отхаркивающие лекарственные средства: принципы выбора и возможности современной фитотерапии. Медицинский совет. 2018;(15):110–115. https://doi.org/10.21518/2079-701X-2018-15-110-115.; Fahy J.V., Dickey B.F. Airway mucus function and dysfunction. N Engl J Med. 2010;363(23):2233–2247. https://doi.org/10.1056/NEJMra0910061.; Aldini G., Altomare A., Baron G., Vistoli G., Carini M., Borsani L, Sergio F. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018;52(7):751–762. https://doi.org/10.10 80/10715762.2018.1468564.; Ehre C., Rushton Z.L., Wang B., Hothem L.N., Morrison C.B., Fontana N.C. et al. An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. Am J Respir Crit Care Med. 2018;199(2):171–180. https://doi.org/10.1164/rccm.201802-0245OC.; Calzetta L., Matera M.G., Rogliani P., Cazzola M. Multifaceted activity of N-acetyll-cysteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018;12(8):693–708. https://doi.org/10.1080/17476348.2018.1495562.; Colombo B., Turconi P., Daffonchio L., Fedele G., Omini C., Cremaschi D. Stimulation of Cl- secretion by the mucoactive drug S-carboxymethylcysteine-lysine salt in the isolated rabbit trachea. Eur Respir J. 1994;7(9):1622–1628. https://doi.org/10.1183/09031936.94.07091622.; Hooper C., Calvert J. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(4):659–669. Available at: https://pubmed.ncbi.nlm.nih.gov/19281081.; Dal Negro R., Pozzi E., Cella S.G. Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases. Pulm Pharmacol Ther. 2018;53:80–85. https://doi.org/10.1016/j.pupt.2018.10.005.; Cazzola M., Calzetta L., Page C., Rogliani P., Matera M.G. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. Trends Pharmacol Sci. 2019;40(7):452–463. https://doi.org/10.1016/j.tips.2019.04.015.; Pizzino G., Irrera N., Cucinotta M., Pallio G., Mannino F., Arcoraci V. et al. Oxidative Stress: Harms and Benefits for Human Health. Oxid Med Cell Longev. 2017;2017:8416763. https://doi.org/10.1155/2017/8416763.; Lee I.T., Yang C.M. Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases. Biochem Pharmacol. 2012;84(5):581–590. https://doi.org/10.1016/j.bcp.2012.05.005.; Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408(6809):239–247. https://doi.org/10.1038/35041687.; Matera M.G., Calzetta L., Cazzola M. Oxidation pathway and exacerbations in COPD: the role of NAC. Expert Rev Respir Med. 2016;10(1):89–97. https://doi.org/10.1586/17476348.2016.1121105.; Cazzola M., Calzetta L., Page C., Rogliani P., Matera M.G. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. Pulm Pharmacol Ther. 2018;48:185–194. https://doi.org/10.1016/j.pupt.2017.11.009.; Rushworth G.F., Megson I.L. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014;141(2):150–159. https://doi.org/10.1016/j.pharmthera.2013.09.006.; Boyaci H., Maral H., Turan G., Başyiğit I., Dillioğlugil M.O., Yildiz F. et al. Effects of erdosteine on bleomycin-induced lung fibrosis in rats. Mol Cell Biochem. 2006;281(1–2):129–137. https://doi.org/10.1007/s11010-006-0640-3.; Demiralay R., Gürsan N., Ozbilim G., Erdogan G., Demirci E. Comparison of the effects of erdosteine and N-acetylcysteine on apoptosis regulation in endotoxin-induced acute lung injury. J Appl Toxicol. 2006;26(4):301–308. https://doi.org/10.1002/jat.1133.; Miyake K., Kaise T., Hosoe H., Akuta K., Manabe H., Ohmori K. The effect of erdosteine and its active metabolite on reactive oxygen species production by inflammatory cells. Inflamm Res. 1999;48(4):205–209. https://doi.org/10.1007/s000110050447.; Gazzani G., Fregnan G.B., Vandoni G. In vitro protection by erdosteine against oxidative inactivation of alpha-1-antitrypsin by cigarette smoke. Respiration. 1989;55(2):113–118. https://doi.org/10.1159/000195713.; Braga P.C., Dal Sasso M., Culici M., Verducci P., Lo Verso R., Marabini L. Effect of metabolite I of erdosteine on the release of human neutrophil elastase. Pharmacology. 2006;77(3):150–154. https://doi.org/10.1159/000094379.; Marchioni C.F., Moretti M., Muratori M., Casadei M.C., Guerzoni P., Scuri R., Fregnan G.B. Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease. Lung. 1990;168(5):285–293. https://doi.org/10.1007/BF02719705.; Анаев Э.Х. Муколитическая терапия: рациональный выбор. Эффективная фармакотерапия. 2010;(27):25–28. Режим доступа: https://elibrary.ru/item.asp?id=21737264.; Геппе Н.А., Снегоцкая М.Н., Никитенко А.А. Ацетилцистеин для лечения кашля у детей. Педиатрия. Приложение к журналу Consilium Medicum. 2007;(2):43–47. Режим доступа: https://medi.ru/info/10711.; Зайцева О.В. Муколитические препараты в терапии болезней органов дыхания у детей: современный взгляд на проблему. РМЖ. 2003;11(1):49–54. Режим доступа: https://www.rmj.ru/articles/pediatriya/Mukoliticheskie_preparaty_v_terapii_bolezney_organov_dyhaniya_u_detey_sovremennyy_vzglyad_na_problemu.; Коровина Н.А., Захарова И.Н., Заплатников А.Л., Овсянникова Е.М. Противокашлевые и отхаркивающие лекарственные средства в практике врача-педиатра: рациональный выбор и тактика применения. 2-е изд., перераб. и доп. М.: РМАПО; 2007. 48 c.; Demiralay R., Gürsan N., Erdem H. The effects of erdosteine and N-acetylcysteine on apoptotic and antiapoptotic markers in pulmonary epithelial cells in sepsis. Eurasian J Med. 2013;45(3):167–175. https://doi.org/10.5152/eajm.2013.35.; Fraňová S., Kazimierová I., Pappová L., Molitorisová M., Jošková M., Šutovská M. The effect of erdosteine on airway defence mechanisms and inflammatory cytokines in the settings of allergic inflammation. Pulm Pharmacol Ther. 2019;54:60–67. https://doi.org/10.1016/j.pupt.2018.11.006.; Dal S.M., Bovio C., Culici M., Braga P.C. The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone. Drugs Exp Clin Res. 2002;28(2–3):75–82. Available at: https://pubmed.ncbi.nlm.nih.gov/12224380.; Braga P.C., Dal Sasso M., Sala M.T., Gianelle V. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittelforschung. 1999;49(4):344–350. https://doi.org/10.1055/s-0031-1300425.; Marchioni C.F., Polu J.M., Taytard A., Hanard T., Noseda G., Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int J Clin Pharmacol Ther. 1995;33(11):612– 618. Available at: https://pubmed.ncbi.nlm.nih.gov/8688986.; Ricevuti G., Mazzone A., Uccelli E., Gazzani G., Fregnan G.B. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax. 1988;43(8):585–590. https://doi.org/10.1136/thx.43.8.585.; Braga P.C., Zuccotti T., Dal Sasso M. Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone. Chemotherapy. 2001;47(3):208–214. https://doi.org/10.1159/000063223.; Dal Negro R., Visconti M., Trevisan F., Bertacco S., Micheletto C., Tognella S. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD. Ther Adv Respir Dis. 2008;2(5):271–277. https://doi.org/10.1177/1753465808096109.; Yunus F., Mangunnegoro H., Rahmawati I., Tjandrawinata R.R., Nofiarny D. The Role of Erdosteine in Reducing the Need for Bronchodilators During Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Journal of the Indonesian Medical Association. 2007;2007:337–345. Available at: https://scholar.ui.ac.id/en/publications/the-role-of-erdosteine-in-reducingthe-need-for-bronchodilators-d.; Авдеев С.Н. Значение мукоактивных препаратов в терапии ХОБЛ. РМЖ. Медицинское обозрение. 2015;(4):206–211. Режим доступа: https://www.rmj.ru/articles/obshchie-stati/Znachenie_mukoaktivnyh_preparatov_v_terapii_HOBL.; Moretti M., Bottrighi P., Dallari R., Da Porto R., Dolcetti A., Grandi P. et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res. 2004;30(4): 143–152. Available at: https://pubmed.ncbi.nlm.nih.gov/15553660.; Rogliani P., Matera M.G., Page C., Puxeddu E., Cazzola M., Calzetta L. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019;20(1):104. https://doi.org/10.1186/s12931-019-1078-y.; Cazzola M., Calzetta L., Puxeddu E., Matera M., Rogliani P. Efficacy of erdosteine, carbocysteine, and N-acetylcysteine in COPD: a comparative analysis. Eur Resp J. 2019;54(63 Suppl.):PA729. https://doi.org/10.1183/13993003.congress-2019.PA729.; Hoza J., Salzman R., Starek I., Schalek P., Kellnerova R. Efficacy and safety of erdosteine in the treatment of chronic rhinosinusitis with nasal polyposis – a pilot study. Rhinology. 2013;51(4):323–327. https://doi.org/10.4193/Rhin13.039.; Santus P., Tursi F., Croce G., Di Simone C., Frassanito F., Gaboardi P. et al. Changes in quality of life and dyspnoea after hospitalization in COVID-19 patients discharged at home. Multidiscip Respir Med. 2020;15(1):713. https://doi.org/10.4081/mrm.2020.713.; https://www.med-sovet.pro/jour/article/view/6347

الاتاحة: https://www.med-sovet.pro/jour/article/view/6347
https://doi.org/10.21518/2079-701X-2021-12-181-191

المؤلفون: E. Kanner V., M. Maksimov L., I. Kanner D., N. Lapkin M., A. Gorelov V., Е. Каннер В., М. Максимов Л., И. Каннер Д., Н. Лапкин М., А. Горелов В.

المصدر: Meditsinskiy sovet = Medical Council; № 11 (2021); 89-98 ; Медицинский Совет; № 11 (2021); 89-98 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: vaccines, vaccination, microbiota, probiotics, Lactobacillus rhamnosus GG, вакцины, вакцинация, микробиота, пробиотики

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6295/5707; Зверев В.В., Хаитов Р.М. (ред.). Вакцины и вакцинация: национальное руководство. М.: ГЭОТАР-Медиа; 2014. 640 с. Режим доступа: https:// www.rosmedlib.ru/book/ISBN9785970428665.html.; Онищенко Т.Т., Ежлова Е.Б., Мельникова А.А. Актуальные проблемы вакцинопрофилактики в Российской Федерации. Журнал микробиологии, эпидемиологии и иммунобиологии. 2014;(1):9–19. Режим доступа: https://cyberleninka.ru/article/n/aktualnye-problemy-vaktsinoprofilaktiki-v-rossiyskoy-federatsii/viewer.; Харсеева Г.Г., Тюкавкина С.Ю. Основы вакцинологии. Оценка поствакцинального иммунитета (материал для подготовки лекции). Инфекционные болезни: новости, мнения, обучение. 2020;9(3):106–118. https://doi.org/10.33029/2305-3496-2020-9-3-106-118.; del Giudice M.M., Leonardi S., Galdo F., Allegorico A., Filippelli M., Arrigo T. et al. Probiotics and Vaccination in Children. J Vaccines Vaccin. 2014;5(3):226. https://doi.org/10.4172/2157-7560.1000226.; Hagan T., Cortese M., Rouphael N., Boudreau C., Linde C., Maddur M.S. et al. Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans. Cell. 2019;178(6):1313–1328.e13. https://doi.org/10.1016/j.cell.2019.08.010.; de Jong S.E., Olin A., Pulendran B. The Impact of the Microbiome on Immunity to Vaccination in Humans. Cell Host Microbe. 2020;28(2):169–179. https://doi.org/10.1016/j.chom.2020.06.014.; Macia L., Tan J., Vieira A.T., Leach K., Stanley D., Luong S. et al. Metabolitesensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun. 2015;6:6734. https://doi.org/10.1038/ncomms7734.; Al Nabhani Z., Dulauroy S., Marques R., Cousu C., Al Bounny S., Déjardin F. et al. A weaning reaction to microbiota is required for resistance to immunopathologies in the adult. Immunity. 2019;50(5):1276–1288.e5. https://doi.org/10.1016/j.immuni.2019.02.014.; An D., Oh S.F., Olszak T., Neves J.F., Avci F.Y., Erturk-Hasdemir D. et al. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell. 2014;156(1-2):123–133. https://doi.org/10.1016/j.cell.2013.11.042.; Jiang W., Wang X., Zeng B., Liu L., Tardivel A., Wei H. et al. Recognition of gut microbiota by NOD2 is essential for the homeostasis of intestinal intraepithelial lymphocytes. J Exp Med. 2013;210(11):2465–2476. https://doi.org/10.1084/jem.20122490.; Atarashi K., Tanoue T., Ando M., Kamada N., Nagano Y., Narushima S. et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell. 2015;163(2):367–380. https://doi.org/10.1016/j.cell.2015.08.058.; Kobayashi T., Voisin B., Kim D.Y., Kennedy E.A., Jo J.H., Shih H.Y. et al. Homeostatic control of sebaceous glands by innate lymphoid cells regulates commensal bacteria equilibrium. Cell. 2019;176(5):982–997.e16. https://doi.org/10.1016/j.cell.2018.12.031.; Stacy A., Belkaid Y. Microbial guardians of skin health. Science. 2019;363(6424):227–228. https://doi.org/10.1126/science.aat4326.; Dickson R.P., Erb-Downward J.R., Martinez F.J., Huffnagle G.B. The microbiome and the respiratory tract. Annu Rev Physiol. 2016;78:481–504. https://doi.org/10.1146/annurev-physiol-021115-105238.; Sandler N.G., Douek D.C. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012;10(9):655–666. https://doi.org/10.1038/nrmicro2848.; Uchimura Y., Fuhrer T., Li H., Lawson M.A., Zimmermann M., Yilmaz B. et al. Antibodies set boundaries limiting microbial metabolite penetration and the resultant mammalian host response. Immunity. 2018;49(3):545–559. e5. https://doi.org/10.1016/j.immuni.2018.08.004.; Li F., Hao X., Chen Y., Bai L., Gao X., Lian Z. et al. The microbiota maintain homeostasis of liver-resident γδT-17 cells in a lipid antigen/CD1ddependent manner. Nat Commun. 2017;7:13839. https://doi.org/10.1038/ncomms13839.; Kim M., Qie Y., Park J., Kim C.H. Gut microbial metabolites fuel host antibody responses. Cell Host Microbe. 2016;20(2):202–214. https://doi.org/10.1016/j.chom.2016.07.001.; Zeng M.Y., Cisalpino D., Varadarajan S., Hellman J., Warren H.S., Cascalho M. et al. Gut microbiota-induced immunoglobulin G controls systemic infection by symbiotic bacteria and pathogens. Immunity. 2016;44(3):647–658. https://doi.org/10.1016/j.immuni.2016.02.006.; Williams W.B., Han Q., Haynes B.F. Cross-reactivity of HIV vaccine responses and the microbiome. Curr Opin HIV AIDS. 2018;13(1):9–14. https://doi.org/10.1097/COH.0000000000000423.; Trama A.M., Moody M.A., Alam S.M., Jaeger F.H., Lockwood B., Parks R. et al. HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe. 2014;16(2):215–226. https://doi.org/10.1016/j.chom.2014.07.003.; Olin A., Henckel E., Chen Y., Lakshmikanth T., Pou C., Mikes J. et al. Stereotypic immune system development in newborn children. Cell. 2018;174(5):1277–1292.e14. https://doi.org/10.1016/j.cell.2018.06.045.; Rampelli S., Candela M., Turroni S., Biagi E., Collino S., Franceschi C. et al. Functional metagenomic profiling of intestinal microbiome in extreme ageing. Aging (Albany, NY). 2013;5(12):902–912. https://doi.org/10.18632/aging.100623.; Goldenberg J.Z., Lytvyn L., Steurich J., Parkin P., Mahant S., Johnston B.C. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015;(12):CD004827. https://doi.org/10.1002/14651858.CD004827.pub4.; Zimmermann P., Curtis N. The influence of probiotics on vaccine responses – A systematic review. Vaccine. 2018;36(2):207–213. https://doi.org/10.1016/j.vaccine.2017.08.069.; Kwak J.Y., Lamousé-Smith E.S.N. Can probiotics enhance vaccine-specific immunity in children and adults? Benef Microbes. 2017;8(5):657–670. https://doi.org/10.3920/bm2016.0147.; Maidens C., Childs C., Przemska A., Dayel I.B., Yaqoob P. Modulation of vaccine response by concomitant probiotic administration. Br J Clin Pharmacol. 2013;75(3):663–670. https://doi.org/10.1111/j.1365-2125.2012.04404.x.; Zens K.D., Chen J.K., Farber D.L. Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight. 2016;1(10):e85832. https://doi.org/10.1172/jci.insight.85832.; Basha S., Surendran N., Pichichero M. Immune responses in neonates. Expert Rev Clin Immunol. 2014;10(9):1171–1184. https://doi.org/10.1586/1744666X.2014.942288.; Galindo-Albarran A.O., Lopez-Portales O.H., Gutierrez-Reyna D.Y., Rodriguez-Jorge O., Sanchez-Villanueva J.A., Ramirez-Pliego O. et al. CD8+ T Cells from human neonates are biased toward an innate immune response. Cell Rep. 2016;17(8):2151–2160. https://doi.org/10.1016/j.celrep.2016.10.056.; Thome J.J., Bickham K.L., Ohmura Y., Kubota M., Matsuoka N., Gordon C. et al. Early-life compartmentalization of human T cell differentiation and regulatory function in mucosal and lymphoid tissues. Nat Med. 2016;22(1):72–77. https://doi.org/10.1038/nm.4008.; Holbrook B.C., D’Agostino Jr. R. B., Parks G.D., Alexander-Miller M.A. Adjuvanting an inactivated influenza vaccine with flagellin improves the function and quantity of the long-term antibody response in a nonhuman primate neonate model. Vaccine. 2016;34(39):4712–4717. https://doi.org/10.1016/j.vaccine.2016.08.010.; Мазанкова Л.Н., Рыбальченко О.В., Корниенко Е.А., Перловская С.Г. Пробиотики в педиатрии: за и против с позиции доказательной медицины. Российский вестник перинатологии и педиатрии. 2016;61(1):16–26. https://doi.org/10.21508/1027-4065-2016-61-1-17-23.; Tao Y., Drabik K.A., Waypa T.S., Musch M.W., Alverdy J.C., Schneewind O. et al. Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells. Am J Physiol Cell Physiol. 2006;290(4):C1018-1030. https://doi.org/10.1152/ajpcell.00131.2005.; Licciardi P.V., Tang M.L. Vaccine adjuvant properties of probiotic bacteria. Discov Med. 2011;12(67):525–533. Available at: https://pubmed.ncbi.nlm.nih.gov/22204769/; De Vrese M., Rautenberg P., Laue C., Koopmans M., Herremans T., Schrezenmeir J. Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination. Eur J Nutr. 2005;44(7):406–413. https://doi.org/10.1007/s00394-004-0541-8.; Davidson L.E., Fiorino A.M., Snydman D.R., Hibberd P.L. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. Eur J Clin Nutr. 2011;65(4):501–507. https://doi.org/10.1038/ejcn.2010.289.; Segers M.E., Lebeer S. Towards a better understanding of Lactobacillus rhamnosus GG – host interactions. Microb Cell Fact. 2014;13(1 Suppl.):S7. https://doi.org/10.1186/1475-2859-13-S1-S7.; Горелов А.В., Каннер Е.В., Максимов М.Л., Ермолаева А.С., Вознесенская А.А., Дадашева К.Н. Кишечная микробиота: современные доказательные данные эффективности применения Lactobacillus rhamnosus GG и Bifidobacterium longum в практике педиатра. Медицинский совет. 2018;(11):175–180. https://doi.org/10.21518/2079701X-2018-11-175-180.; Калюжин О.В. Пробиотические штаммы лактобацилл как иммуномодуляторы: в фокусе – Lactobacillus Rhamnosus GG. Медицинский совет. 2017;(9):108–115. https://doi.org/10.21518/2079701X-2017-9-108-115.; Rocha-Ramírez L.M., Hernández-Chiñas U., Moreno-Guerrero S.S., RamírezPacheco A., Eslava C.A. Probiotic Properties and Immunomodulatory Activity of Lactobacillus Strains Isolated from Dairy Products. Microorganisms. 2021;9(4):825. https://doi.org/10.3390/microorganisms9040825.; Корниенко Е.А., Дроздова С.Н., Серебряная Н.Б. Пробиотики как способ повышения эффективности эрадикации Helicobacter pylori у детей. Фарматека. 2005;(7):68–70. https://pharmateca.ru/ru/archive/article/5998.; Mojgani N., Shahali Y., Dadar M. Immune modulatory capacity of probiotic lactic acid bacteria and applications in vaccine development. Benef Microbes. 2020;11(3):213–226. https://doi.org/10.3920/bm2019.0121.; https://www.med-sovet.pro/jour/article/view/6295

الاتاحة: https://www.med-sovet.pro/jour/article/view/6295
https://doi.org/10.21518/2079-701X-2021-11-89-98

المؤلفون: Ekaterina Kanner V., Aleksandr Gorelov V., Maksim Maksimov L., Ilya Kanner D., Nikita Lapkin M., Е. Каннер В., А. Горелов В., М. Максимов Л., И. Каннер Д., Н. Лапкин М.

المصدر: Meditsinskiy sovet = Medical Council; № 1 (2021); 149-156 ; Медицинский Совет; № 1 (2021); 149-156 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: antibacterials, antibiotics, antibiotic-associated diarrhea, dehydration, Lactobacillus rhamnosus GG, антибактериальные препараты, антибиотики, антибиотик-ассоциированная диарея, дегидратация

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6041/5507; Романова О.Н., Довнар-Запольская О.Н., Преображенская О.А., Матуш Л.И., Сергей Ж.С., Манкевич Р.Н. и др. Антибиотико ассоци ированная диарея у детей, обусловленная Clostridium difficilt-инфекцией: клинические особенности, диагностика и лечение. Клиническая инфектология и паразитология. 2020;9(1):50–70. doi:10.34883/PI.2020.9.1.005.; Захарова И.Н., Бережная И.В., Сугян Н.Г. Антибиотик-ассоциированные диареи у детей: что нового? Медицинский совет. 2017;(19):126–133.doi:10.21518/2079-701X-2017-19-126-133.; Харченко О.Ф. Антибиотикоассоциированная диарея у детей: новые возможности лечения. Международные обзоры: клиническая практика и здоровье.2014;(3):82–88. Режим доступа: https://elibrary.ru/item.asp?id=21978635.; Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. N Eng J Med. 2002;346(5):334–339. doi:10.1056/NEJMcp011603.; Barakat M., El-Kady Z., Mostafa M., Ibrahim N, Ghazaly H. Antibioticassociated Bloody Diarrhea in Infants: Clinical, Endoscopic and Histopathologic Profiles. J Pediatr Gastroenterol Nutr. 2011;52(1):60–64. doi:10.1097/MPG.0b013e3181da215b.; Успенский Ю.П., Фоминых Ю.А. Антибиотик-ассоциированная диарея: актуальность проблемы, профилактика и терапия. Архивъ внутренней медицины. 2013;2(10):46–53. doi:10.20514/2226-6704-2013-0-2-46-53.; Пинегин Б.В., Хаитов Р.М. Современные принципы создания иммуно-тропных лекарственных препаратов. Иммунология. 2019;40(6):57–62. doi:10.24411/0206-4952-2019-16008.; Hooper L.V. Do symbiotic bacteria subvert host immunity? Nat Rev Microbiol. 2009;7(5):367–374. doi:10.1038/nrmicro2114.; Wlodarska M., Finlay B. Host immune response to antibiotic perturbation of the microbiota. Mucosal Immunol. 2010;3(2):100–103. doi:10.1038/mi.2009.135.; Плоскирева А.А., Горелов А.В., Голден Л.Б. Антибиотик-ассоциированная диарея: патогенетические аспекты терапии и профилактики. РМЖ. 2017;(19):1381–1384. Available at: https://rmj.ru/articles/pediatriya/Antibiotik-associirovannaya_diareya_patogeneticheskie_aspekty_terapii_i_profilaktiki.; Захарова И.Н., Борзова Е.Ю., Симакова М.А. Lactobacillus rhamnosus GG: опыт применения в детской гастроэнтерологической практике. Российский вестник перинатологии и педиатрии. 2019;64(6):20–29.doi:10.21508/1027-4065-2019-64-6-20-29.; Hurley B.W., Nguyen C.C. The spectrum of pseudomembra-nous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med. 2002;162(19):2177–2184. doi:10.1001/archinte.162.19.2177.; Szajewska H., Kołodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015;42(10):1149–1157. doi:10.1111/apt.13404.; Goldenberg J.Z., Lytvyn L., Steurich J., Parkin P., Mahant S., Johnston B.C. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015;(12):CD004827. doi:10.1002/14651858.CD004827.pub4.; Blaabjerg S., Artzi D.M., Aabenhus R. Probiotics for the prevention of antibiotic-associated diarrhea in outpatients – a systematic review and metaanalysis. Antibiotics (Basel).2017;6(4):21. doi:10.3390/antibiotics6040021.; Guarner F., Sanders M.E., Eliakim R., Fedorak R., Gangl A., Garisch J. et al. WGO Practice Guidelines – Probiotics and prebiotics. 2017. Available at: https://worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics.; Charteris W.P., Kelly P.M., Morelli L., Collins J.K. Gradient diffusion antibiotic susceptibility testing of potentially probiotic lactobacilli. J Food Prot. 2001;64(12):2007–2014. doi:10.4315/0362-028x-64.12.2007.; Shah N.P. Probiotic bacteria: selective enumeration and survival in dairy foods. J Dairy Sci. 2000;83(4):894–907. doi:10.3168/jds.S0022-0302(00)74953-8.; Глушанова Н.А. Биологические свойства лактобацилл. Бюллетень сибирской медицины. 2003;2(4):50–58. doi:10.20538/1682-0363-2003-4-50-58.; Lu R., Fasano S., Madayiputhiya N., Morin N.P., Nataro J., Fasano A. Isolation, Identification, and Characterization of Small Bioactive Peptides From Lactobacillus GG Conditional Media That Exert Both Anti-Gramnegative and Gram-positive Bactericidal Activity. J Pediatr Gastroenterol Nutr. 2009;49(1):23–30. doi:10.1097/MPG.0b013e3181924d1e.; Guarino A., Ashkenazi Sh., Gendrel D., Lo Vecchio A., Shamir R., Szajewska H. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases Evidencebased Guidelines for the Management of Acute Gastroenteritis in Children in Europe. J Pediatr Gastroenterol Nutr. 2014;59(1):132–152. doi:10.1097/MPG.0000000000000375.; Segers M.E., Lebeer S. Towards a better understanding of Lactobacillus rhamnosus GG – host interactions. Microb Cell Fact. 2014;13(1 Suppl.):7. doi:10.1186/1475-2859-13-S1-S7.; Hatakka K., Savilahti E., Ponka A., Meurman J.H., Poussa T., Näse L. et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ. 2001;322(7298):1327. doi:10.1136/bmj.322.7298.1327.; Hojsak I., Snovak N., Abdovic S., Szajewska H., Misak Z., Kolacek S. et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2010;29(3):312–316. doi:10.1016/j.clnu.2009.09.008.; Андреева И.В. Современные доказательные данные эффективности применения Lactobacillus Rhamnosus GG и Bifidobacterium LactisВB-12 в педиатрической практике. Вопросы современной педиатрии. 2011;10(1):50–57. Режим доступа: https://vsp.spr-journal.ru/jour/article/view/539/466.; https://www.med-sovet.pro/jour/article/view/6041

الاتاحة: https://www.med-sovet.pro/jour/article/view/6041
https://doi.org/10.21518/2079-701X-2021-1-149-156

المؤلفون: A. Snigireva V., S. Noskov M., M. Maksimov L., А. Снигирева В., С. Носков М., М. Максимов Л.

المصدر: Meditsinskiy sovet = Medical Council; № 21 (2019); 224-230 ; Медицинский Совет; № 21 (2019); 224-230 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-21

مصطلحات موضوعية: osteoarthritis, pathogenesis, bone marrow edema, magnetic resonance imaging, therapy, остеоартрит, патогенез, отек костного мозга, магнитно-резонансная томография, лечение

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5498/5017; Кабалык М.А. Распространенность остеоартрита в России: региональные аспекты динамики статистических показателей за 2011– 2016 гг. Научно-практическая ревматология. 2018;56(4):416–422. doi:10.14412/1995-4484-2018-416-422. Kabalyk M.A. Prevalence of osteoarthritis in Russia: regional aspects of trends in statistical parameters during 2011–2016. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(4):416–422. (In Russ.) doi:10.14412/1995-4484-2018-416-422.; Neogi T., Zhang Y. Epidemiology of OA. Rheum Dis Clin North Am. 2013;39(1):1–19. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545412/; Woolf A.D., Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646–656. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14710506.; Runhaar J., Zhang Y. Can we prevent OA? Epidemiology and public health insights and implications. Rheumatology. 2018;57(Suppl4):iv3–iv9. doi:10.1093/rheumatology/key014.; Каратеев А.Е., Лила А.М. Остеоартрит: современная клиническая концепция и некоторые перспективные терапевтические подходы. Научно-практическая ревматология. 2018;56(1):70–81. Режим доступа: https://rsp.ima-press.net/rsp/article/view/2502. Karateev A.E., Lila A.M. Osteoarthritis: current clinical concept and some promising therapeutic approaches. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):70–81 (In Russ.) Available at: https://rsp.ima-press.net/rsp/article/view/2502.; Loeser R.F., Goldring S.R., Scanzello C.R., Goldring M.B. Osteoarthritis: A disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697–1707. Available at: https://www.scirp.org/reference/ReferencesPapers.aspx?ReferenceID=2235058.; Rowbotham E.L., Grainger A.J. Magnetic Resonance Imaging of Arthritis of the Knee. Semin Musculoskelet Radiol. 2017.21(2):113– 121. doi:10.1055/s-0037-1599213.; Costa-Paz M., Muscolo D., Ayerza M., Makino A., Aponte-Tinao L. Magnetic resonance imaging follow-up study of bone bruises associated with anterior cruciate ligament ruptures. Arthroscopy. 2001;17(5):445–449. doi:10.1053/jars.2001.23581.; Rosenberg J.H., Rai V., Dilisio M.F., Agrawal D.K. Damage-associated Molecular Patterns in the Pathogenesis of Osteoarthritis: Potentially Novel Therapeutic Targets. Mol Cell Biochem. 2017;434(1-2):171–179. doi:10.1007/s11010-017-3047-4.; Boks S.S., Vroegindeweij D., Koes B.W., Hunink M.G.M., Bierma-Zeinstra S.M.A. Follow-up of occult bone lesions detected at MR imaging: Systematic review. Radiology. 2006;238:853–862. doi:10.1148/radiol.2382050062.; Zanetti M., Bruder E., Romero J., Hodler J. Bone marrow edema pattern in osteoarthritic knees: Correlation between MR imaging and histologic findings. Radiology. 2000;215:835–840. doi:10.1148/radiology.215.3.r00jn05835.; Felson D.T., McLaughlin S., Goggins J., LaValley M.P., Gale M.E., Totterman S., et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med. 2003;139:330–336. doi:10.7326/0003-4819-139-5_part_1-200309020-00008.; Hunter D.J., Zhang Y., Niu J., Goggins J., Amin Sh., LaValley M.P., et al. Increase in bone marrow lesions associated with cartilage loss. Arthritis Rheum. 2006;54(5):1529–1535. doi:10.1002/art.21789.; Link T., Steinbach L., Ghosh S., Ries M., Ying Lu, Lane N., Majumdar Sh. Osteoarthritis: MR imaging findings in different stages of disease and correlation with clinical findings. Radiology. 2003;226:373–381. Available at: doi:10.1148/radiol.2262012190.; Kornaat P.R., Bloem J.L., Ceulemans R.T., Riyazi N., Rosendaal F.R., Nelissen R.G. Osteoarthritis of the knee: association between clinical features and MR imaging findings. Radiology. 2006;239:811–817. doi:10.1148/radiol.2393050253.; Aigner N., Meizer R., Meraner D., Becker S., Radda C., Landsiedl F. Tapping test in patients with painful bone marrow edema of the knee. Clin J Pain. 2008;24(2):131–134. doi: 00002508-200802000-00007.; Bergman A.G., Willen H.K., Lindstrand A.L., Petterson H.T. Osteoarthritis of the knee; correlation of subchondral MR signal abnormalities with histopathologic and radiographic features. Skelet Radiol. 1994;23(6):445–448.doi:10.1007/BF00204605.; Thiryayi W.A., Thiryayi S.A., Freemont A.J. Histopathological perspective on bone marrow oedema reactive bone change and haemorrhage. Eur J Radiol.2008;67(1):62–67. doi:10.1016/j.ejrad.2008.01.056.; Starr A.M., Wessely M.A., Albastaki U., Pierre- Jerome C., Kettner N.W. Bone marrow edema: pathophysiology, differential diagnosis, and imaging. Acta Radiol. 2008;49(7):771–786. doi:10.1080/02841850802161023.; Klement M.R., Sharkey P.F. The Significance of Osteoarthritis-associated Bone Marrow Lesions in the Knee. J Am Acad Orthop Surg. 2019;27(20):752–759. doi:10.5435/JAAOS-D-18-00267.; Crema M.D., Roemer F.W., Zhu Y., Marra M.D., Niu J., Zhang Y., et al.` Subchondral cystlike lesions develop longitudinally in areas of bone marrow edema-like lesions in patients with or at risk for knee osteoarthritis: detection with MR imaging – the MOST study. Radiology. 2010;256(3):855–862. doi:10.1148/radiol.10091467.; Scher C., Craig J., Nelson F. Bone marrow edema in the knee in osteoarthrosis and association with total knee arthroplasty within a three-year follow-up. Skeletal Radiol. 2008;37(7):609–617. doi:10.1007/s00256-008-0504-x.; Garnero P., Peterfy C., Zaim S., Schoenharting M. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum. 2005;52(9):2822–2829. doi:10.1002/art.21366.; Perry T.A., Parkes M.J., Hodgson R., Felson D.T., O’Neill T.W., Arden N.K. Effect of Vitamin D supplementation on synovial tissue volume and subchondral bone marrow lesion volume in symptomatic knee osteoarthritis. BMC Musculoskelet Disord. 2019;20(1):76. doi:10.1186/s12891-019-2424-4.; Laslett L.L., Doré D.A., Quinn S.J., Boon P., Ryan E., Winzenberg T.M., Jones G. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Annals of the Rheumatic Diseases. 2012;71:1322–1328. doi:10.1136/annrheumdis-2011-200970.; Varenna M., Zucchi F., Failoni S., Becciolini A., Berruto M. Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study. Rheumatology. 2015;54(10):1826–1832. doi:10.1093/rheumatology/kev123.; Cai G., Laslett L.L., Aitken D., Cicuttini F., March L., Hill C., Winzenberg T., Jones G. Zoledronic acid plus methylprednisolone versus zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial. Ther Adv Musculoskelet Dis. 2019;11:1759720X19880054. DOI:10.1177/1759720X19880054.; Kraenzlin M.E., Graf C., Meier C., Kraenzlin C., Friedrich N.F. Possible beneficial effect of bisphosphonates in osteonecrosis of the knee. Knee Surg Sports Traumatol Arthrosc. 2010;18(12):1638–1644. doi:10.1007/s00167-010-1106-4.; Meier C., Kraenzlin C., Friederich N.F., Wischer T., Grize L., Meier C.R., Kraenzlin M.E. Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo- controlled trial. Osteoporos Int. 2014;25(1):359–366. doi:10.1007/s00198-013-2581-5.; Mayerhoefer M.E., Kramer J., Breitenseher M.J., Norden C., Vakil-Adli A., Hofmann S., Meizer R., et al. MRI-demonstrated outcome of subchondral stress fractures of the knee after treatment with iloprost or tramadol: observations in 14 patients. Clin J Sport Med. 2008;18(4):358–362. doi:10.1097/JSM.0b013e31817f3e1c.; Baier C., Schaumburger J., Gotz J., Heers G., Schmidt T., Grifka J., Beckmann J. Bisphosphonates or prostacyclin in the treatment of bone-marrow oedema syndrome of the knee and foot. Rheumatol Int. 2013;33(6):1397–1402. DOI:10.1007/s00296-012-2584-0.; Kumagai K., Shirabe S., Miyata N., Murata M., Yamauchi A., Kataoka Y., Niwa M. Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis – an open clinical trial. BMC Clin Pharmacol. 2010;10:7. doi:10.1186/1472-6904-10-7.; Ghosh P., Edelman J., March L., Smith M. Effects of pentosan polysulfate in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled pilot study. Curr Ther Res Clin Exp. 2005;66(6):552–571. doi:10.1016/j.curtheres.2005.12.012.; Sampson M.J., Kabbani M., Krishnan R., Nganga M., Theodoulou A., Krishnan J. Improved clinical outcome measures of knee pain and function with concurrent resolution of subchondral Bone Marrow Edema Lesion and joint effusion in an osteoarthritic patient following Pentosan Polysulphate Sodium treatment: a case report. BMC Musculoskelet Disord. 2017;18(1):396. doi:10.1186/s12891-017-1754-3.; Sunaga T., Oh N., Hosoya K., Takagi S., Okumura M. Inhibitory effects of pentosan polysulfate sodium on MAP-kinase pathway and NF-kappaB nuclear translocation in canine chondrocytes in vitro. J Vet Med Sci. 2012;74(6):707–711. doi:10.1292/jvms.11-0511.; Troeberg L., Mulloy B., Ghosh P., Lee M.H., Murphy G., Nagase H. Pentosan polysulfate increases affinity between ADAMTS-5 and TIMP- 3 through formation of an electrostatically driven trimolecular complex. Biochem J. 2012;443(1):307–315. doi:10.1042/BJ20112159.; Ghosh P., Cheras P.A. Vascular mechanisms in osteoarthritis. Best Pract Res Clin Rheumat. 2001;15(5):693–709. doi:10.1053/berh.2001.0188.; Ghosh P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum. 1999;28(4):211–267. doi:10.1016/S0049-0172(99)80021-3.; Nielsen F.K., Boesen M., Jurik A.G., Bliddal H., Nybing J.D., Ellegaard K., et al. The effect of intra-articular glucocorticosteroids and exercise on symptoms and bone marrow lesions in kneeosteoarthritis: a secondary analysis of results from a randomized controlled trial. Osteoarthritis Cartilage. 2018;26(7):895–902. doi:10.1016/j.joca.2018.02.900.; McAlindon T.E., LaValley M.P., Harvey W.F., Price L.L., Driban J.B., Zhang M., Ward R.J. Effect of intraarticular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: A randomized clinical trial. JAMA.2017;317(19):1967–1975. doi:10.1001/jama.2017.5283.; Wildi L.M., Raynauld J., Martel-Pelletier J., Beaulieu A., Bessette L., Morin F., et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Annals of the Rheumatic Diseases. 2011;70(6):982–989. doi:10.1136/ard.2010.140848.; https://www.med-sovet.pro/jour/article/view/5498

الاتاحة: https://www.med-sovet.pro/jour/article/view/5498
https://doi.org/10.21518/2079-701X-2019-21-224-230

المؤلفون: D. Gudz O., A. Krasnov E., R. Mamleev N., R. Kagirov K., M. Maximov L., Д. Гудз О., А. Краснов Е., Р. Мамлеев Н., Р. Кагиров К., М. Максимов Л.

المساهمون: The study was performed with no external funding., Исследование проводилось без спонсорской поддержки.

المصدر: Safety and Risk of Pharmacotherapy; Том 7, № 2 (2019); 93-98 ; Безопасность и риск фармакотерапии; Том 7, № 2 (2019); 93-98 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2019-7-2

مصطلحات موضوعية: interferon beta-1b, meta-analysis, multiple sclerosis, therapeutic equivalence, biosimilars, adverse drug reactions, интерферон бета-1b, метаанализ, рассеянный склероз, терапевтическая эквивалентность, биоаналог, нежелательные реакции

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/140/153; Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014;83(11):1022–4. https://doi.org/10.1212/WNL.0000000000000768; Paty DW, Hartung HP, Ebers GC, Soelberg-Sorensen P, Abramsky O, Kesselring J, et al. Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines. Eur J Neurol. 1999;6(suppl 1):1–35.; Гринхальх Т. Основы доказательной медицины. М.: ГЭОТАР-Медиа; 2015.; Байдина ЕВ, Бойко АН, Брюхов ВВ, Гусев ЕИ, Дубчак ЛВ, Завалишин ИА и др. Результаты клинического исследования российского биоаналога интерферона-бета-1b. Неврологический вестник. 2010;42(1):41–8.; Хабиров ФА, Бабичева НН, Хайбуллин ТИ, Аверьянова ЛА, Гранатов ЕВ, Ахмедова ГМ. Опыт применения биоаналога интерферона бета-1b для лечения рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(9):113–22.; Попова ЕВ, Бойко АН, Васильев АВ, Давыдовская МВ, Завалишин ИА, Котов СВ и др. Результаты клинического исследования препарата Инфибета (II–III фаза). Рекомендации по переводу пациентов с рассеянным склерозом на биоаналоги. Consilium medicum. 2012;14(2):120–5.; https://www.risksafety.ru/jour/article/view/140

الاتاحة: https://www.risksafety.ru/jour/article/view/140
https://doi.org/10.30895/2312-7821-2019-7-2-93-98

المؤلفون: T. Bukatina M., E. Pasternak Yu., B. Romanov K., R. Alyautdin N., V. Lepakhin K., A. Kazakov S., K. Zatolochina E., I. Snegireva I., M. Darmostukova A., E. Kolesnikova Yu., E. Zhuravleva O., T. Romanova V., N. Velts Yu., M. Maximov L., G. Kutekhova V., Т. Букатина М., Е. Пастернак Ю., Б. Романов К., Р. Аляутдин Н., В. Лепахин К., А. Казаков С., К. Затолочина Э., И. Снегирева И., М. Дармостукова А., Е. Колесникова Ю., Е. Журавлева О., Т. Романова В., Н. Вельц Ю., М. Максимов Л., Г. Кутехова В.

المصدر: Safety and Risk of Pharmacotherapy; Том 5, № 1 (2017); 39-43 ; Безопасность и риск фармакотерапии; Том 5, № 1 (2017); 39-43 ; 2619-1164 ; 2312-7821 ; undefined

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/66/67; https://www.risksafety.ru/jour/article/view/66; undefined

الاتاحة: https://www.risksafety.ru/jour/article/view/66

المؤلفون: M. Maksimov L., S. Simakova A., М. Максимов Л., С. Симакова А.

المصدر: Safety and Risk of Pharmacotherapy; Том 6, № 2 (2018); 68-77 ; Безопасность и риск фармакотерапии; Том 6, № 2 (2018); 68-77 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2018-6-2

مصطلحات موضوعية: words: dietary supplements, hepatotoxicity, adverse reactions, anabolic steroids, ephedr, биологически активные добавки, БАД, гепатотоксичность, нежелательные реакции, анаболические стероиды, эфедра

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/103/104; Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF. Dietary supplement use by US adults: Data from the National Health and Nutrition Examination Survey: 1999–2000. Am. J. Epidemiol. 2004; 160: 339–49.; Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, et al. Dietary supplement use in the United States: 2003–2006. J. Nutr. 2011; 141: 261–6. DOI:10.3945/jn.110.133025; Garcia-Alvarez A, Egan B, de Klein S, Dima L, Maggi FM, et al. Usage of plant food supplements across six European countries: Findings from the PlantLIBRA consumer survey. PLoSONE. 2014; 9: 537.; Serafini M, Stanzione A, Foddai S, Anton R, Delmulle L. The European role on traditional herbal medicinal products and traditional plant food supplements. J. Clin. Gastroenterol. 2012; 46: S93–4.; European Medicines Agency Committee on Herbal Medicinal Products (HMPC) [(accessed on 13 January 2014)]. Available online: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_con-tent_000264.jsp; Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512–21.; García-Cortés M, Borraz Y, Lucena MI, Peláez G, Salmerón J, et al. Liver injury induced by “natural remedies”: An analysis of cases submitted to the Spanish Liver Toxicity Registry. Rev. Esp. Enferm. Dig. 2008; 100: 688–95.; Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419–25. DOI:10.1053/j.gastro.2013.02.006; Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 2014; 60: 1399–408. DOI:10.1002/hep.27317; Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am. J. Gastroenterol. 2012; 107: 1380–7.; Wai CT, Tan BH, Chan CL, Sutedja DS, Lee YM, et al. Drug-induced liver injury at an Asian center: A prospective study. Liver Int. 2007; 27: 465–74.; Zhou Y, Yang L, Liao Z, He X, Guo H. Epidemiology of drug-induced liver injury in China: A systematic analysis of the Chinese literature including 21,789 patients. Eur. J. Gastroenterol. Hepatol. 2013; 25: 825–9.; Stickel F, Kessebohm K, Weimann R, Seitz HK. Review of liver injury associated with dietary supplements. Liver Int. 2011; 31: 595–605.; Commission on Dietary Supplement Labels Chapter I Dietary Supplement Health And Education Act of 1994. [(accessed on 13 January 2014)]; Available online: http://www.health.gov/dietsupp/ch1.htm.; Danan G, Benichou C. Causality assessment of adverse reactions to drugs. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J. Clin. Epidemiol. 1993; 46: 1323–30.; Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 2014; 60: 1399–408.; Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, Stephens C, García-Cortes M, et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment. Pharmacol. Ther. 2015.; Ishak KG. Hepatic lesions caused by anabolic and contraceptive steroids. Semin. Liver Dis. 1981; 1: 116–28.; Singh V, Rudraraju M, Carey EJ, Byrne TJ, Vargas HE, et al. Severe hepatotoxicity caused by a methasteron-containing performance-enhancing supplement. J. Clin. Gastroenterol. 2009.; Timcheh-Hariri A, Balali-Mood M, Aryan E, Sadeghi M, Riahi-Zanjani B. Toxic hepatitis in a group of 20 male body-builders taking dietary supplements. Food Chem. Toxicol. 2012.; Krishnan PV, Feng ZZ, Gordon SC. Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroid-enriched dietary supplements. J. Clin. Gastroenterol. 2009.; Turani H, Levi J, Zevin D, Kessler E. Hepatic lesions in patients on anabolic androgenic therapy. Isr. J. Med. Sci. 1983.; Patil JJ, O’Donohoe B, Loyden CF, Shanahan D. Near-fatal spontaneous hepatic rupture associated with anabolic androgenic steroid use: A case report. Br. J. Sports Med. 2007.; Agbenyefia P, Arnold CA, Kirkpatrick R. Cholestatic Jaundice With the Use of Methylstenbolone and Dymethazine, Designer Steroids Found in Super DMZ Rx 2.0 “Nutritional Supplement” A Case Report III. J. Investig. Med. High Impact Case Rep. 2014.; Hymel BM, Victor DW, Alvarez L, Shores NJ, Balart LA. Mastabol induced acute cholestasis: A case report. World J. Hepatol. 2013.; Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin. Liver Dis. 1987.; Brazeau MJ, Castaneda JL, Huitron SS, Wang J. A Case Report of Supplement-Induced Hepatitis in an Active Duty Service Member. Mil. Med. 2015.; Sánchez-Osorio M, Duarte-Rojo A, Martínez-Benítez B, Torre A, Uribe M. Anabolic-androgenic steroids and liver injury. Liver Int. 2008.; Gavilan JC, Bermudez FJ, Salgado F, Pena D. Phytotherapy and hepatitis. Rev. Clin. Esp. 1999; 199: 693–4.; Pillukat MH, Bester C, Hensel A, Lechtenberg M, Petereit F, et al. Concentrated green tea extract induces severe acute hepatitis in a 63-year-old woman. A case report with pharmaceutical analysis. J. Ethnopharmacol. 2014; 155: 165–70.; Molinari M, Watt KD, Kruszyna T, Nelson R, Walsh M, et al. Acute liver failure induced by green tea extracts: Case report and review of the literature. Liver Transpl. 2006; 12: 1892–5.; Verhelst X, Burvenich P, Van Sassenbroeck D, Gabriel C, Lootens M, Baert D. Acute hepatitis after treatment for hair loss with oral green tea extracts (Camellia sinensis) Acta Gastroenterol. Belg. 2009; 72: 262–4.; Patel SS, Beer S, Kearney DL, Phillips G, Carter BA. Green tea extract: A potential cause of acute liver failure. World J. Gastroenterol. 2013; 19: 5174–7.; Lorenzo-Almorós A, Polo-Sabau J, Barrio-Dorado MP, Ruggiero GM. Acute liver injury induced by green tea extracts. Gastroenterol. Hepatol. 2015; 38: 44–5.; Bjornsson E, Olsson R. Serious adverse liver reactions associated with herbal weight-loss supplements. J. Hepatol. 2007; 47: 295–7.; Abu el Wafa Y, Benavente Fernández A, Talavera Fabuel A, Pérez Ramos MA, Ramos-Clemente JI. Acute hepatitis induced by Camellia sinensis (green tea) An. Med. Interna. 2005; 22: 298.; García-Morán S, Sáez-Royuela F, Gento E, López Morante A, Arias L. Acute hepatitis associated with Camellia thea and Orthosiphon stamineusingestión. Gastroenterol. Hepatol. 2004; 27: 559–60.; Dueñas Sadornil C, Fabregas Puigtió S, Durández R. Hepatotoxicity due to Camelia sinensis. Med. Clin. 2004; 122: 677–8.; Thiolet C, Mennecier D, Bredin C, Moulin O, Rimlinger H, et al. Acute cytolysis induced by Chinese tea. Gastroenterol. Clin. Biol. 2002; 26: 939–40.; Weinstein DH, Twaddell WS, Raufman JP, Philosophe B, Mindikoglu AL. SlimQuick™-associated hepatotoxicity in a woman with α-1 antitrypsin heterozygosity. World J. Hepatol. 2012; 4: 154–7.; Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, et al. Safety of green tea extracts. A systematic review by the US pharmacopeia. Drug Saf. 2008; 31: 469–84.; Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, Mastrangelo S. Hepatotoxicity from green tea: A review of the literature and two unpublished cases. Eur. J. Clin. Pharmacol. 2009; 65: 331–41.; Galati G, Lin A, Sultan AM, O’Brien PJ. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic. Biol. Med. 2006; 40: 570–80.; Gloro R, Hourmand-Ollivier I, Mosquet B, Mosquet L, Rousselot P, et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur. J. Gastroenterol. Hepatol. 2005; 17: 1135–7.; Pedrós C, Cereza G, García N, Laporte JR. Liver toxicity of Camellia sinensis dried etanolic extract. Med. Clin. 2003; 121: 598–9.; Ramos R, Mascarenhas J, Duarte P, Vicente C, Casteleiro C. Conjugated linoleic acid-induced toxic hepatitis: First case report. Dig. Dis. Sci. 2009; 54: 1141–3.; Nortadas R, Barata J. Fulminant hepatitis during self-medication with conjugated linoleic acid. Ann Hepatol. 2012; 11: 265–7.; Bilal M, Patel Y, Burkitt M, Babich M. Linoleic Acid Induced Acute Hepatitis: A Case Report and Review of the Literature. Case Rep. Hepatol. 2015.; Neff GW, Reddy KR, Durazo FA, Meyer D, Marrero R, Kaplowitz N. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J. Hepatol. 2004; 41: 1062–4.; Herbalife. [(accesed on 9 January 2016)]. Available online: http://ir.herbalife.com/releasedetail.cfm?ReleaseID=891717.; Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, et al. Herbal does not mean innocuous: Ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J. Hepatol. 2007; 47: 521–6.; Elinav E, Pinsker G, Safadi R, Pappo O, Bromberg M, et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J. Hepatol. 2007; 47: 514–20.; Duque JM, Ferreiro J, Salgueiro E, Manso G. Hepatotoxicity associated with the consumption of herbal slimming products. Med. Clin. 2007; 128: 238–9.; Manso G, López-Rivas L, Duque JM, Salgueiro E. Испанские сообщения о гепатотоксичности, связанной с продуктами Гербалайф. J. Hepatol. 2008; 49: 289–90. DOI:10.1016/j.jhep.2008.05.007; Manso G, López-Rivas L, Duque JM, Salgueiro E. Spanish reports of hepatotoxicity associated with Herbalife products. J. Hepatol. 2008; 49: 289–90.; Chao S, Anders M, Turbay M, Olaiz E, McCormack L, Mastai R. Toxic hepatitis by consumption Herbalife products a case report. Acta Gastroenterol. Latinoam. 2008; 38: 274–7.; Chen GC, Ramanathan VS, Law D, Funchine P, Chen GC, et al. Acute liver injury induced by weight-loss herbal supplements. World J. Hepatol. 2010; 2: 410-5. DOI:10.4254/wjh.v2.i11.410; Mengual-Moreno E, Lizarzábal-García M, RuizSoler M, Silva-Suarez N, Andrade-Bellido R, et al. Case reports of drug-induced liver injury in a reference hospital of Zulia state, Venezuela. Investig. Clin. 2015; 56: 3–12.; Stickel F, Droz S, Patsenker E, Bögli-Stuber K, Aebi B, Leib SL. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J. Hepatol. 2009; 50: 111–7.; Olson JA. Vitamin A. In: Ziegler EE, Filer LJ Jr, eds. Present Knowledge in Nutrition. 7th ed. International Life Sciences Institute; Washington, DC, USA: 2001.; Hathcock JN, Hattan DG, Jenkins MY, McDonald JT, Sundaresan PR, Wilkening VL. Evaluation of vitamin A toxicity. Am. J. Clin. Nutr. 1990; 52: 183–202.; Penniston KL, Tanumihardjo SA. The acute and chronic effects of vitamin A. Am. J. Clin. Nutr. 2006; 83: 191–201.; Carpenter TO, Pettifor JM, Russell RM, Pitha J, Mobarhan S, et al. Severe hypervitaminosis A in siblings: Evidence of variable tolerance to retinol intake. J. Pediatr. 1987; 111: 507–12. DOI:10.1016/S0022-3476(87)80109-9; Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin A administration: Estimate of dose-related toxicity in 41 cases. Gastroenterology. 1991; 100: 1701–9.; Ramanathan VS, Hensley G, French S, Eysselein V, Chung D, et al. Hypervitaminosis A inducing intra-hepatic cholestasis. A rare case report. Exp. Mol. Pathol. 2010; 88: 324–5. DOI:10.1016/j.yexmp.2009.11.007; Becker P, Maurer B, Schirmacher P, Waldherr R, Parlesak A, et al. Vitamin A induced cholestatic hepatitis: A case report. Z Gastroenterol. 2007; 45: 1063–6. DOI:10.1055/s-2007-963342; Kowalski TE, Falestiny M, Furth E, Malet PF. Vitamin A hepatotoxicity: A cautionary note regarding 25,000 IU supplements. Am. J. Med. 1994; 97: 523–8. DOI:10.1016/00029343(94)90347-6; Croquet V, Pilette C, Lespine A, Vuillemin E, Rousselet MC, et al. Hepatic hyper-vitaminosis A: Importance of retinyl ester level determination. Eur. J. Gastroenterol. Hepatol. 2000; 12: 361–4. DOI:10.1097/00042737-200012030-00016; Nollevaux MC, Guiot Y, Horsmans Y, Leclercq I, Rahier J, et al. Hypervitaminosis A-induced liver fibrosis: Stellate cell activation and daily dose consumption. Liver Int. 2006; 26: 182–6. DOI:10.1111/j.1478-3231.2005.01207.x; Muenter MD, Perry HO, Ludwig J. Chronic vitamin A intoxication in adults. Hepatic, neurologic and dermatologic complications. Am. J. Med. 1971; 50: 129–36. DOI:10.1016/0002-9343(71)90212-9.; Russell RM, Boyer JL, Bagheri SA, Hruban Z. Hepatic injury from chronic hypervitaminosis a resulting in portal hypertension and ascites. N. Engl. J. Med. 1974; 291: 435–40. DOI:10.1056/NEJM197408292910903; Jacques EA, Buschmann RJ, Layden TJ. The histopathologic progression of vitamin A-induced hepatic injury. Gastroenterology. 1979; 76: 599–602.; Herbert V. Will questionable nutrition overwhelm nutrition science? Am. J. Clin. Nutr. 1981; 34: 2848–53.; Farris WA, Erdman JW. Protracted hypervitaminosis A following long-term, low-level intake. J. Am. Med. Assoc. 1982; 247: 1317. DOI:10.1001/jama.1982.03320340071041; Weber FL, Mitchell GE, Powell DE, Reiser BJ, Banwell JG. Reversible hepatotoxicity associated with hepatic vitamin A accumulation in a protein-deficient patient. Gastroenterology. 1982; 82: 118–23.; Hatoff DE, Gertler SL, Miyai K, Parker BA, Weiss JB. Hypervitaminosis A unmasked by acute viral hepatitis. Gastroenterology. 1982; 82: 124–8.; Park HM, Ransburg R, Roth C, Meadows J. Scintigraphic dissociation of reticuloendothelial and hepatocyte function in chronic vitamin A hepatotoxicity. Clin. Nucl. Med. 1985; 10: 364–6.; Inkeles SB, Connor WE, Illingworth DR. Hepatic and dermatologic manifestations of chronic hypervitaminosis A in adults. Report of two cases. Am. J. Med. 1986; 80: 491–6.; Vincent LM. Scintigraphic dissociation of reticuloendothelial and hepatocyte function in chronic vitamin A hepatotoxicity. Clin. Nucl. Med. 1986; 11: 67.; Witzleben CL. Case 5. Vitamin A hepatotoxicity. Pediatr. Pathol. 1986; 6: 481–4.; Krasinski SD, Russell RM, Otradovec CL, Sadowski JA, Hartz SC, et al. Relationship of vitamin A and vitamin E intake to fasting plasma retinol, retinol-binding protein, retinyl esters, carotene, alpha-tocopherol, and cholesterol among elderly people and young adults: Increased plasma retinyl esters among vitamin A-supplement users. Am. J. Clin. Nutr. 1989; 49: 112–20.; Corey R, Werner KT, Singer A, Moss A, Smith M, Noelting J, Rakela J. Acute liver failure associated with Garcinia cambogia use. Ann. Hepatol. 2015; 15: 123–6.; Melendez-Rosado J, Snipelisky D, Matcha G, Stancampiano F. Acute hepatitis induced by pure Garcinia cambogia. J. Clin. Gastroenterol. 2015; 49: 449–50.; Олефир ЮВ, Медуницын НВ, Авдеева ЖИ, Солдатов АА, Мовсесянц АА, и др. Современные биологические/биотехнологические лекарственные препараты. Актуальные вопросы разработки и перспективы использования. БИОпрепараты. Профилактика, диагностика, лечение 2016; 16(2): 67–77.; Бурова ЕД, Ходько СВ, Гущина СВ, Макарова МН, Макарова ВГ. Управление рисками для обеспечения качества доклинических исследований лекарственных средств. ведомости Научного центра экспертизы средств медицинского применения 2017; 7 (1): 25–32. .; https://www.risksafety.ru/jour/article/view/103

الاتاحة: https://www.risksafety.ru/jour/article/view/103
https://doi.org/10.30895/2312-7821-2018-6-2-68-77

المؤلفون: T. Bukatina M., E. Pasternak Yu., B. Romanov K., R. Alyautdin N., V. Lepakhin K., A. Kazakov S., K. Zatolochina E., I. Snegireva I., M. Darmostukova A., E. Zhuravleva O., T. Romanova V., N. Velts Yu., M. Maksimov L., D. Kaperko A., G. Kutekhova V., Т. Букатина М., Е. Пастернак Ю., Б. Романов К., Р. Аляутдин Н., В. Лепахин К., А. Казаков С., К. Затолочина Э., И. Снегирева И., М. Дармостукова А., Е. Журавлева О., Т. Романова В., Н. Вельц Ю., М. Максимов Л., Д. Каперко А., Г. Кутехова В.

المصدر: Safety and Risk of Pharmacotherapy; Том 5, № 3 (2017); 133-139 ; Безопасность и риск фармакотерапии; Том 5, № 3 (2017); 133-139 ; 2619-1164 ; 2312-7821 ; undefined

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/82/83; https://www.risksafety.ru/jour/article/view/82; undefined

الاتاحة: https://www.risksafety.ru/jour/article/view/82

المؤلفون: T. Bukatina M., E. Pasternak Yu., B. Romanov K., R. Alyautdin N., V. Lepakhin K., A. Kazakov S., K. Zatolochina E., I. Snegireva I., M. Darmostukova A., E. Kolesnikova Yu., E. Zhuravleva O., T. Romanova V., N. Velts Yu., M. Maksimov L., G. Kutekhova V., Т. Букатина М., Е. Пастернак Ю., Б. Романов К., Р. Аляутдин Н., В. Лепахин К., А. Казаков С., К. Затолочина Э., И. Снегирева И., М. Дармостукова А., Е. Колесникова Ю., Е. Журавлева О., Т. Романова В., Н. Вельц Ю., М. Максимов Л., Г. Кутехова В.

المصدر: Safety and Risk of Pharmacotherapy; № 4 (2016); 31-40 ; Безопасность и риск фармакотерапии; № 4 (2016); 31-40 ; 2619-1164 ; 2312-7821 ; undefined

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/60/61; https://www.risksafety.ru/jour/article/view/60; undefined

الاتاحة: https://www.risksafety.ru/jour/article/view/60

المؤلفون: K. Gyamdzhyan A., V. Kukes G., M. Maksimov L., К. Гямджян А., В. Кукес Г., М. Максимов Л.

المصدر: Meditsinskiy sovet = Medical Council; № 7 (2017); 63-68 ; Медицинский Совет; № 7 (2017); 63-68 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-7

مصطلحات موضوعية: chronic heart failure, biomarkers, galectin-3, NT-proBNP, хроническая сердечная недостаточность, биомаркеры, галектин-3

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1771/1715; Агеев Ф.Т., Арутюнов Г.П., Беленков Ю.Н. и др. Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа, 2010. 336 с.; Ho JE, Liu C, Lyass A et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol, 2012, 60(14): 1249-1256.; Агеев Ф.Т., Азизова А.Г. Галектин-3 – новый биохимический маркер сердечной недостаточности. Журнал Сердечная Недостаточность, 2011, 12 (2): 108–114.; Николаева М.В., Кургузова Д.О. Механизм образования натрийуретического пептида у больных ХСН. Лекарственные препараты и рациональная фармакотерапия, 2015, 4-5.; Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA, 2006, 103: 5060–5.; Liu YH, d’Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, et al. N-Acetyl-seryl-aspartyllysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growthregulatory lectin. Am J Physiol Heart Circ Physiol, 2009, 296: H404–12.; de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep, 2010, 7: 1-8.; Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation, 2004, 110: 3121–8.; Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol, 2011, 108: 385–90.; Ueland T, Aukrust P, Broch K, Aakhus S, Skardal R, Muntendam P, et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol, 2011, 150: 361–4.; Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail, 2012, 14: 74–81.; Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Мареев Ю.В., Овчинников А.Г. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность, 2013, 14(7): 379–472.; Lok DJ, Van Der Meer P, de la Porte PW et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol, 2010, 99(5): 323–328.; Felker GM, Fiuzat M, Shaw LK et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail, 2012, 5(1): 72–78.; Biomarker Definitions Working Group. Biomarkers and surrogate end-points: preffered definitions and conceptual framework. Clin Pharmacol Ther, 2001, 69(3): 89–95.; O’Hanlon R et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail, 2007 Feb, 13(1): 50-5.; McCullough PA et al. Galectin-3: A Novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med, 2011, 12(4): 200-210.; Calvier L et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Atheroscler Thromb Vasc Biol, 2013, 33(1): 67–75; Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, Badings E, Lipsic E, van Wijngaarden J et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol, 2013, 102(2): 103–110.; De Boer RA, Lok DJA, Jaarsma T, van der Meer P, Voors AA, Hillege HL et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med., 2011, 43(1): 60–68.; Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol, 2008, 172: 288-298.; https://www.med-sovet.pro/jour/article/view/1771

الاتاحة: https://www.med-sovet.pro/jour/article/view/1771
https://doi.org/10.21518/2079-701X-2017-7-63-68

المؤلفون: K. Gyamdzhyan A., M. Maksimov L., К. Гямджян А., М. Максимов Л.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 8, No 6 (2012); 826-830 ; Рациональная Фармакотерапия в Кардиологии; Vol 8, No 6 (2012); 826-830 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2012-8-6

مصطلحات موضوعية: renin-angiotensin-aldosterone system, sartans, angiotensin converting enzyme inhibitors, pharmacotherapy of cardiovascular diseases, captopril, enalapril, ramipril, losartan, valsartan, irbesartan, endothelial function, atherosclerosis, ренин-ангиотензин-альдостероновая система, сартаны, ингибиторы ангиотензин-превращающего фермента, фармакотерапия сердечно-сосудистых заболеваний, каптоприл, эналаприл, рамиприл, лозартан, валсартан, ирбесартан, эндотелиальная функция, атеросклероз

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/644/667; Davis J.O. The second Volhard Lecture: the use of blocking agents to define the functions of the reninangiotensin system. Clin Sc Mol Med Suppl 1975; 2:3s–14s.; Gavras H., Brunner H.R., Turini G.A. et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298(18):991–5.; Dzau V.J. Antman E.M., Black H.R. et al. The cardiovascular disease continuum validated: clinical evidence of improved patients outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114(25):2850–70.; Ageev F.T., Arutyunov G.P., Belenkov Yu.N. Chronic heart failure. Moscow: GEOTAR-Media; 2010. Russian (Агеев Ф.Т., Арутюнов Г.П., Беленков Ю.Н. Хроническая сердечная недостаточность. М: ГЕО-ТАР-Медиа; 2010).; Skvortsov A.A., Mareev V.Yu., Belenkov Yu.N. Place of angiotensin II receptor blockers in the treatment of patients with CHF. Serdtse 2008; (5): 275–83. Russian (Скворцов А.А., Мареев В.Ю., Беленков Ю.Н. Место блокаторов рецепторов ангиотензина II в лечении больных ХСН. Сердце 2008; (5): 275–83).; Belenkov Yu.N. Mareev V.Yu. Ageev F.T. Chronic heart failure. Selected lectures on cardiology. Moscow: GEOTAR-Media; 2006. Russian (Беленков Ю.Н. Мареев В.Ю. Агеев Ф.Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. М: ГЕОТАР-Медиа; 2006).; Ostroumova O.D., Maksimov M.L., Shchukina G.N., Shorikova E.G. Receptor antagonists angiotenzinuIIv 2010: what's new? Sistemnye Gipertenzii 2011; (1): 12–15. Russian (Остроумова О.Д., Максимов М.Л., Щукина Г.Н., Шорикова Е.Г. Антагонисты рецепторов к ангиотензинуIIв 2010: что нового? Системные Гипертензии 2011; (1): 12–15).; Maksimov M.L., Dralova O.V., Starodubtsev A.K. AT1-receptor antagonists, angiotensin II, an-giotensin-converting enzyme in the regulation of hemodynamics and the renin-angiotensin-aldosterone system. Focus on organoprotective effects. Kardiovaskulyarnaya Terapiya i Profilaktika 2010; 9(2): 115– 124. Russian (Максимов М.Л., Дралова О.В., Стародубцев А.К. Антагонисты АТ1-рецепторов ангиотензина II, ингибиторы ангиотензин-превращающего фермента в регуляции гемодинамики и активности ренин-ангиотензин-альдостероновой системы. Фокус на органопротективные эффекты. Кардиоваскулярная Терапия и Профилактика 2010; 9(2): 115–124).; Kobalava Zh.D., Kotovskaya Yu.V., Moiseev V.S. Hypertension. The keys to the diagnosis. Moscow: GEOTAR-Media; 2009. Russian (Кобалава Ж.Д., Котовская Ю.В., Моисеев В.С. Артериальная гипертензия. Ключи к диагностике. M: ГЕОТАР-Медиа; 2009).; Kobalava Zh.D., Shavarova E.K. AngiotenzinuII receptor antagonists in cardiology practice: a modern approach to the problem. Russkiy Meditsinskiy Zhurnal 2008; (11): 1609–15. Russian (Кобалава Ж.Д., Шаварова Е.К. Антагонисты рецепторов к ангиотензинуII в кардиологической практике: современный взгляд на проблему. Русский Медицинский Журнал 2008; (11): 1609–15).; The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the North Scandinavian Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429–35.; Lindholm L.H., Ibsen H., Dahlof B. et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359(9311):1004–10.; Mochizuki S, Dahlof B, Taniguchi I et al. for the JIKEI HEART Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–9.; Parving HH, Lenhert H, Bröchner-Mortensen J, et al. The effects of irbesartan on the development of diabetic nephropathy in patients with types 2 diabetes. N Engl J Med 2001;345(12):870–8; Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60.; Viberti G., Wheeldom N.M. MicroAlbuminuria Reduction With Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type II diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106(6):672–8.; Brenner B.M., Cooper M.E., de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2001;345(12):851–60.; Schrader J, Lüders S, Kulschewski A et al. Morbidity and Mortality after Stroke, Eprosartan compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36(2):1218–1226.; Julius S., Kjeldsen S.E., Weber M. et al Outcome in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004;363(9426):2022–31.; The NAVIGATOR Study Group. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med 2010; 362:1477–90.; Hollenberg NK, Parving HH, Viberti G, Remuzzi G. The Diovan reduction of Proteinuria Drop study: Albuminuria response to high doses of Valsartan in Type 2 Diabetes Mellitus. Circulation 2006; 114:II– 61; National guidelines for the diagnosis and treatment of hypertension (fourth revision). Sistemnye Gipertenzii 2010; (3): 5–26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5–26).; Pitt B., Poole-Wilson P.A., Segal R. et al. Effect of losartan compared to captopril on mortality in patients with symptomatic heart failure; randomized trial — the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355(9215):1582–7; Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Lancet 2002;360(9335):752–60; Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–906; Cohn J.N., Tognoni G. Valsartan Heart Failure Trial Investigator. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23):1667–75; Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–776.; Baker W.L., Coleman C.I., Kluger J., et al. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II–Receptor Blockers for Ischemic Heart Disease. Ann Intern Med 2009;151:861–871; Matchar DB, McCory DC, Orlando LA, et al Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. Ann Intern Med 2008;148:16–29.; Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med 2008;148:30–48.; Yusuf S., Teo K.K., Pogue J et al.; ONTARGET Investigators. Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547–59; Wang L, Huang XS, Zhou YL et al. Effects of angiotensin blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study. Di Yi Jun Yi Da Xue Xue Bao 2005;25(8):967–71.; https://www.rpcardio.com/jour/article/view/644

الاتاحة: https://www.rpcardio.com/jour/article/view/644
https://doi.org/10.20996/1819-6446-2012-8-6-826-830

المؤلفون: O. Dralova V., M. Maksimov L., О. Дралова В., М. Максимов Л.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 7, No 4 (2011); 468-472 ; Рациональная Фармакотерапия в Кардиологии; Vol 7, No 4 (2011); 468-472 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2011-7-4

مصطلحات موضوعية: arterial hypertension, gout, valsartan, amlodipine, aliskiren, артериальная гипертония, подагра, валсартан, амлодипин, алискирен

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/863/896; Vazguez-Mellado J., Garsia C.G., Vazguez S.G. et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol 2004; 10 (3):105–109.; Eliseev M.S., Barskova V.G., Nassonova V.A., Nassonov E.L. Insulin resistance syndrome in patients with gout and its influence on uric acid concentration and severity of arthritis. Ann Rheum Dis 2006; 65 (Suppl II): 432.; Choi H.K., Ford E.S., Li С., Curhan G. Prevalence of the Metabolic Syndrome in Patients With Gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57:109-115.; Høieggen A., Alderman M.H., Kjeldsen S.E. et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65(3): 1041-1049.; Reyes A.J. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003;17(5–6): 397–414.; Kobalava Zh.D., Tolkacheva V.V. Uric acid is a key link cardiorenal continuum? Part I. Klinicheskaya farmakologiya i terapiya 2003; 12: 15–19. Russian (Кобалава Ж.Д., Толкачева В.В. Мочевая кислота — ключевое связующее звено кардиоренального континуума? Часть I. Клиническая фармакология и терапия 2003; 12: 15–19).; Perlstein T.S., Gumieniak O., Hopkins P.N., et al. Uric acid and the state of the intrarenal renin–angiotensin system in humans. Kidney Int 2004; 66:1465–1470.; Takahashi S., Moriwaki Y., YamamotoT. et al. Effects of combination treatment using anti–hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62: 572–575.; Taylor W. Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia. Clin med 2002; 80(2): 77–78.; Mychka V.B., Blinova N.V., Chazova I.E. Effective antihypertensive therapy in patients with metabolic syndrome. Sistemnye gipertenzii 2010; 3:71-75. Russian (Мычка В.Б., Блинова Н.В., Чазова И.Е.Эффективная антигипертензивная терапия у больных с метаболическим синдромом. Системные гипертензии 2010; 3:71-75).; Karpov Yu.A., Chazova I.E., Vigdorchik A.V. Efficacy and security of a fixed combination of amlodipine and valsartan in the treatment of hypertension in clinical practice: results of the Russian observational study EKSTRA-2. Sistemnye gipertenzii 2010;4:14-21. Russian (Карпов Ю.А., Чазова И.Е., Вигдорчик А.В. Эфективность и безопасность фиксированной комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: результаты Российского наблюдательного исследования ЭКСТРА-2. Системные гипертензии 2010;4:14-21).; Chazova I.E., Fomin V.V., Razuvaeva M.A., Vigdorchik A.V. Resistant and uncontrolled hypertension in the Russian Federation: epidemiological characteristics and treatment approaches (Russian Register of uncontrolled and resistant hypertension REGATTA "Resistant Arterial Hypertension"). Kardiologicheskiy vesnik 2011; VI (1): 40-48. Russian (Чазова И.Е., Фомин В.В., Разуваева М.А., Вигдорчик А.В. Резистентная и неконтролируемая артериальная гипертония в Российской Федерации: эпидемиологическая характеристика и подходы к лечению (Российский регистр неконтролируемой и резистентной артериальной гипертонии РЕГАТА «Резистентная Гипертония Артериальная»). Кардиологический вестник 2011; VI (1): 40-48).; Jordan J., Engeli S., Boye S.W. et al. Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension. Hypertension 2007; 49(5): 1047-1055.; Abbott R.D., Brand F.N., Kannel W.B., Castelli W.P. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988; 41:237–242.; https://www.rpcardio.com/jour/article/view/863

الاتاحة: https://www.rpcardio.com/jour/article/view/863
https://doi.org/10.20996/1819-6446-2011-7-4-468-472

المؤلفون: L. Maksimova N., M. Maksimov L., Y. Nartsissov R., R. Zaslavskaya M., E. Kalinina V., Л. Максимова Н., М. Максимов Л., Я. Нарциссов Р., Р. Заславская М., Е. Калинина В.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 9, No 5 (2013); 577-581 ; Рациональная Фармакотерапия в Кардиологии; Vol 9, No 5 (2013); 577-581 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2013-9-5

مصطلحات موضوعية: chronic heart failure, metabolite therapy, glutathione, хроническая сердечная недостаточность, метаболитная терапия, глутатион

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/241/313; National guidelines for the diagnosis and treatment of chronic heart failure (3rd revision). Heart Failure 2010; 11 (1):1-57. Russain (Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (3-й пересмотр). Сердечная Недостаточность 2010;11(1):1-57).; Chazova EI, Belenkov YuN. Rational pharmacotherapy of cardiovascular diseases. Moscow: Litterra; 2005. Russian (Чазова Е.И., Беленков Ю.Н. Рациональная фармакотерапия сердечнососудистых заболеваний. М.: Литтерра; 2005).; The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.; Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction/ results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.; Kober L, Torp-Pedersen C, Carlsen JE et al. Effect on mortality by trandolapril after myocardial infarction. N Engl J Med 1995; 333: 1670-6.; Jong P, Yusuf S, Rousseau MF et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361: 1843-8.; Packer M, Antonopoulos GV, Berlin JA et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure results of meta-analysis1. Am Heart J 2001; 141: 899-907.; Lilitsa GV, Zaslavskaya RM, Kalinina EV. The effectiveness of metabolic drugs in treatment of elderly patients with myocardial infarction, and heart failure. Clinical Medicine 2005; 83 (3): 54-7. Russian (Лилица Г.В., Заславская Р. М., Калинина Е.В. Эффективность метаболических препаратов в комплексном лечении пожилых больных постинфарктным кардиосклерозом и недостаточностью кровообращения. Клиническая Медицина 2005; 83(3): 54-7).; Amosova EN. Metabolic therapy myocardial injury caused by myocardial ischemia. A new approach to the treatment to the treatment of ischemic heart disease and heart failure. Ukrainian Journal of Car- diology 2000; (4): 86-92. Russian (Амосова Е.Н. Метаболическая терапия повреждений миокарда, обусловленных ишемией миокарда. Новый подход к лечению к лечению ишемической болезни сердца и сердечной недостаточности. Украинский Кардиологический Журнал 2000; (4): 86-92).; Nikonov VV, Pavlenko AYu. Metabolic therapy of hypoxic conditions. Medical Emergency Conditions 2009; (3): 22-3. Russian (Никонов В.В., Павленко А.Ю. Метаболическая терапия гипоксических состояний. Медицина Неотложных Состояний 2009; (3): 22-3).; Kosarev VV, Babanov SA. The clinical pharmacology of modern cardiocytoprotectors. Russian Medical Journal 2011; 19 (26): 1619-23. Russian (Косарев В.В., Бабанов А.О. Особенности клинической фармакологии современных кардиоцитопротекторов. Русский Медицинский Журнал 2011; 19(26): 1619-23); Simonenko VB. Antioxidants in the treatment of myocardial infarction. Clinical Medicine 1998; 76 (11): 20-5. Russian (Симоненко В.Б. Антиоксиданты в комплексной терапии инфаркта миокарда. Клиническая Медицина 1998; 76(11): 20-5).; Nagornev VA. The role of antioxidants in the treatment of elderly patients with coronary artery disease. Russian Journal of Medicine 2011, 9 (18): 767-9. Russian (Нагорнев В.А. Роль антиоксидантов в комплексной терапии пожилых больных ИБС. Русский Медицинский Журнал 2011; 9(18): 767-9).; Korneev AA. The role of glutathione in the formation of the metabolic response of the cells to hypoxia. Proceedings of the Academy of Sciences, Series Biology 1993; (4): 542-9. Russian (Корнеев А. А. Роль глутатиона в формировании метаболического ответа клетки на гипоксию. Известия Академии Наук, Серия Биология 1993; (4): 542-9).; Korneev AA, Nartsissov JR. The use of glutathione as a sacrificial agent in hypoxic exposure. Bulletin Experimental Biology and Medicine 1993; (9): 261-3. Russian (Корнеев А. А., Нарциссов Я. Р. Использование глутатиона в качестве протекторного средства при гипоксическом воздействии. Бюллютень Экспериментальной Биологии и Медицины 1993; (9): 261-3).; Korneev AA. Some aspects of the molecular regulation of cellular mitochondrial respiratory chain. Proceedings of the Academic of Sciences, Series Biology 1994; (3): 363-74. Russian (Корнеев А. А. Некоторые аспекты молекулярной клеточной регуляции дыхательной цепи митохондрий. Известия Академических Наук, Серия Биология 1994;(3): 363-74).; Korneev AA. On the mechanism of the damaging effect of hypoxia on the respiratory chain and methods of its pharmacological correction. Experimental and Clinical Pharmacology 1994; 57 (1): 45-7. Russian (Корнеев А. А. О механизме повреждающего действия гипоксии на дыхательную цепь и способах ее фармакологической коррекции. Экспериментальная и Клиническая Фармакология 1994; 57(1): 45-7).; Gusev EI, Skvortsov VI. Cerebral ischemia. Moscow: Medicine; 2001. Russian (Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина; 2001).; Petrov VI, Grigoriev IA, Adzhienko VL, Yanitskaya AV. Stress-protective properties of new analogs of neurotransmitter amino acids. Experimental and Clinical Pharmacology 1996; 59 (5): 6-8. Russian (Петров В.И. Григорьев И.А., Аджиенко В.Л., Яницкая А.В. Стресспротекторные свойства новых аналогов медиаторных аминокислот. Экспериментальная и Клиническая Фармакология 1996; 59(5): 6-8).; Wise S., Buttrick Mawner T et al. Beneficial impact of specific substances on cardiac: reperfusion injury in vitro. Clin Nut 1992;11: 71.; Shmerelson MB, Boyarinov GA, Pichurin VV. Protection of pre ischemic heart glutamic acid in cardiopulmonary bypass. Anesthesiology and Resuscitation 1990; (2): 3-7. Russain (Шмерельсон М.Б., Бояринов Г.А., Пичурин В.В. Предишемическая защита сердца глутаминовой кислотой в условиях искусственного кровообращения. Анестезиология и Реаниматология 1990;(2): 3-7).; Arzamastcev EV, Gus'kova TA, Rudakov AG, et al. Guidelines for the Study of general toxic effect of pharmacological substances. Bulletin of the Pharmacological Committee 1998; (1): 27-32. Russian (Арзамасцев Е.В., Гуськова Т.А., Рудаков А.Г., и др. Методические указания по изучению об- щетоксического действия фармакологических веществ. Ведомости Фармакологического Комитета 1998; (1): 27-32).; Berezovskaya IV, Balynina ES. Comparative evaluation of methods of approximate estimation of the rats in toxicological experiments. Pharmacology and Toxicology 1976; (5): 20. Russian (Березовская И.В., Балынина Е.С. Сравнительная оценка методов ориентировочной оценки крыс в ток- сикологическом эксперименте. Фармакология и Токсикология 1976; (5): 20).; Zaslavskaya RM, Komissarova IA, Kalinina EV, et al. Evaluation of amino acid metabolite complex therapy in patients with coronary heart disease elderly. Clinical Medicine 1999; 77 (4) :46-9. Russian (Заславская Р.М., Комиссарова И.А., Калинина Е.В., и др. Оценка эффективности метаболитной терапии комплексом аминокислот у больных ишемической болезнью сердца пожилого возраста. Клиническая Медицина 1999;77(4):46-9).; Kalinina EV, Zaslavskaya RM. Eltatcin antioxidant effect in the treatment of elderly patients with coronary artery disease. Collection of scientific and practical work of employees of City Clinical Hospital; № 60. Moscow: Overlay; 2007: 118-120. Russian (Калинина Е.В. Заславская Р.М. Антиоксидантный эффект Элтацина в терапии больных ИБС пожилого возраста. Сборник научно-практических работ сотрудников городской клинической больницы № 60. М.: Оверлей; 2007: 118-120).; Kalinina EV, Komissarova IA, Zaslavskaya RM, Lilitsa GV. The influence of the drug metabolite Eltatsin on oxidative level of elderly patients with coronary artery disease. Clinical Gerontology 2003; 9 (9); Russian (Калинина Е.В., Комиссарова И.А., Заславская Р.М., Лилица Г.В. Влияние метаболитного препарата Элтацин на оксидантный уровень больных ИБС пожилого возраста. Клиническая Геронтология 2003; 9(9): 9).; National guidelines for the diagnosis and treatment of stable angina. Cardiovascular Therapy and Prevention 2008, 7 (6) suppl 4: 1-45. Russian (Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная Терапия и Профилактика 2008; 7(6), Приложение 4: 1-45).; Zaslavsky RM, Scherban EA, MM Teyblyum Optimization of treatment of weather and magnetical- ly sensitive hypertensive patients with coronary artery disease with the use of adaptogens. Moscow: Medpraktika; 2012. Russain (Заславская Р.М., Щербань Э.А., Тейблюм М.М. Оптимизация лечения метео- и магниточувствительных больных артериальной гипертензией и ишемической болезнью сердца с использованием адаптогенов. М.: Медпрактика; 2012).; https://www.rpcardio.com/jour/article/view/241

الاتاحة: https://www.rpcardio.com/jour/article/view/241
https://doi.org/10.20996/1819-6446-2013-9-5-577-581

المؤلفون: M. Maksimov L., S. Sologova S., М. Максимов Л., С. Сологова С.

المصدر: Meditsinskiy sovet = Medical Council; № 18 (2015); 84-89 ; Медицинский Совет; № 18 (2015); 84-89 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2015-18

مصطلحات موضوعية: НПВП, противовоспалительные средства, обезболивающие препараты, болевой синдром, нимесулид, декскетопрофен, эффективность, безопасность, пожилые пациенты, NSAIDs, anti-inflammatory drugs, analgesics, pain, nimesulide, dexketoprofen, efficacy, safety, elde

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/459/459; Кукушкин М.Л., Табеева Г.Р., Подчуфарова Е.В. Болевой синдром: патогенез, клиника, лечение. Клинические рекомендации. под ред. акад. РАМН Н.Н.Яхно. М.: Има-пресс, 2011, 79 с.; IASP Committee on Taxonomy, 2012 -Международная ассоциация по изучению боли IASP http//www.iasp-pain.org.; Осипова Н.А., Абузарова Г.Р., Петрова В.В. Принципы применения анальгетических средств при острой и хронической боли. Клинические рекомендации. М.: ФГБУ «МНИОИ им. П.А. Герцена Минздравсоцразвития России», 2010. 67 с.; Максимов М.Л. Современные подходы к терапии болевого синдрома. Русский мед. журнал. 2013. 21, 34: 1734-1736.; Баринов А.Н., Яхно Н.Н. Лечение невропатической боли. Русский медицинский журнал, 2003. 25: 1419-1424.; Кукушкин М.Л., Хитров Н.К. Общая патология боли. М.: Медицина, 2004. 144 с.; Левин О.С. Болевой синдром при полиневропатиях. Справочник поликлинического врача. 2007. 1: 56-62.; Яхно Н.Н. (ред.). Боль. Медпресс-информ. 2009. 304 с.; American Geriatrics Society Panel. Pharmacological мападете of persistent pain in older persons. JAGS, 2009. 57: 1331-1346.; Dworkin RH, O'Connor AB, Backonja M et al. Pharmacologic management of neuropathic pain: Evidence-based rec-ommendations. Pain. 2007. 132: 237-251.; Helme RD, Gibson SJ. The epidemiology of pain in elderly people. Clin.Geriatr. Med. 2001. 17: 417-431.; Miro J et al. European Journal of Pain. 2007. 11: 83-92.; Thomas E, Peat G, Harris L et al. The prevalence of pain and pain interference in a general population of older adults. Pain. 2004. 110: 361-368.; Клиническая фармакология и фармакотерапия. Под ред. В.Г. Кукеса, А.К. Стародубцева. М.: ГЭОТАР-Медиа, (2012) 832 с.; Champion G.D, Feng P.H, Azuma T. et al. NSAID-induced gastrointestinal damage. Drugs, 1997, 53: 6-19.; Страчунский Л.С., Козлов С.Н. Нестероидные противовоспалительные средства http://www. antibiotic.ru/rus/all/metod/npvs.; Клиническая фармакология: национальное руководство (Серия «Национальные руководства»). М.: ГЭОТАР-Медиа, 2009. 976 с.; Журавлева М.В. Актуальные вопросы применения нестероидных противовоспалительных средств: возможности применения ацеклофе-нака. Фарматека, 2011, 9.; Laurence DR, Bennett PN. Clinical Pharmacology. 7th ed. Churcill Livingstone, 1992.; Нестероидные противовоспалительные средства. (Редакц. статья). Клин. фармакол. и фар-макотер., 1994, 3: 6-7; Loeb DS, Ahlquist DA, Talley NJ. Management of gastroduo-denopathy associated with use of nonsteroidal anti-inflammatory drugs. Mayo Clin. Proc., 1992, 67: 354-364.; Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001 Sep. 12(5): 570-6.; Boers M, Tangelder MJ, van Ingen H et al. The rate of NSAID-induced.endoscopic ulcers increases linearly but not exponen-tially with age: A pooled analysis of 12 randomised trials. Ann Rheum Dis. 2007. 66: 417-418.; Franceschi M, Scarcelli C, Niro V et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 1756 patients. Drug Saf. 2008. 31: 545-556.; Евсеев М.А. Повреждение кишечной трубки нестероидными противовоспалительными препаратами: клиническое значение, патогенез, возможности профилактики. Неврология, ней-ропсихиатрия, психосоматика. 2013. 1: 79-87; Максимов М. Л. Место миорелаксантов в лечении болевого синдрома. Русский медицинский журнал, 2014, 7: 514-517; Morris AJ, Madhok R, Sturrock RD et al. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal antiinflammatory drugs. Lancet. 1991. 337: 520.; Kessler WF, Shires GT, Fahey TJ. Surgical complications of non-steroidal anti-inflammatory drug-induced small bowel ulceration. J. Am. Coll. Surg. 1997. 185(3): 250-254.; Graham DY, Opekun AR, Willingham FF et aLVisible small-intestinal mucosal injury in chronic NSAID users. Clin. Gastroenterol. Hepatol. 2005. 3: 55-59.; Hawkey CJ, Ell C, Simon Beal. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin. Gastroenterol. Hepatol. 2008. 536.; Hawkey CJ. NSAIDs, coxibs, and the intestine. J. Cardiovasc. Pharmacol. 2006. 47 (Suppl. 1): 72-75.; Maiden L, Thjodleifsson B, Seigal A et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin. Gastroenterol. Hepatol. 2007. 5: 1040-1045.; Matsumoto T, Kudo T, Esaki M et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand. J. Gastroenterol. 2008. 43: 490-496.; Abdominal Imaging, January-February 1998, 23, 1: 40-44.; Парфенов В.А. Диагноз и лечение при острых болях в нижней части спины. РМЖ. 2007. 6.; Berry H, Hutchinson DR. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. J Int Med Res. 1988. 16: 75-82.; Пасечников В.Д. Механизмы защиты слизистой оболочки желудка и NO-высвобождающие нестероидные противовоспалительные препараты. Consilium Medicum. 2013, 9.; Каратеев А.Е. Амтолметин гуацил: можно ли создать «улучшенный» НПВП? Медицинский совет, 2013, 12.; Насонов ЕЛ., Каратеев А.Е. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. РМЖ, 2006, 5.; Ливзан М.А., Осипенко М.Ф., Лялюкова Е.А. Поражение органов пищеварения у пациентов, принимающих нестероидные противовоспалительные препараты: факторы риска, тактика ведения. Лечащий врач, 2013, 7.; Каратеев А.Е. Целекоксиб, эторикоксиб, мелокси-кам и нимесулид: достоинства и недостатки. Ревматология. Травматология. Ортопедия, 2011. 1.; Rainsford KD. Current status of the therapeutic uses and actions of the preferential cyclo-oxy-genase-2 NSAID, nimesulide. Inflammopharmacology. 2006, 14(3-4): 120-137; Насонов Е.Л. Эффективность и переносимость нестероидного противовоспалительного препарата. Нимесулид: новые данные. РМЖ, 2001, 15: 6-8.; Camu F, Shi L, Vanlesberghe C. The role of COX-2 inhibitors in pain modulation. Drag., 2003, 63, suppl. 1: 1-7.; Барскова В.Г., Якунина И.А., Насонова В.А. Применение нимесила при подагрическом артрите. Тер. Архив. 2003, 5: 60-64.; Renard J, Julemont F, de Leval X, Pirotte B. The use of nimesulide and its analogues in cancer chemoprevention. Anticancer Agents Med Chem. 2006, 6(3): 233-237.; Masferrer1 J, Leahy K, Koki A et al. Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors. Cancer Research. 2000, 60: 1306-1311.; Fodera D, D'Alessandro N, Cusimano A et al. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N YAcad Sci., 2004, 1028: 440-449.; Pan Y, Zhang J, Gazi M, Young C. The cyclooxy-genase 2-specific nonsteroidal antiinflammato-ry drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiol Biomarkers Prev., 2003, 12(8): 769-774.; Grimes K, Warren G, Fang F, Xu Y, St Clair W. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo. Oncol Rep., 2006, 16(4): 771-776.; Nakatsugi S, Ohta T, Kawamori T et al. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-me-thyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn. J. Cancer Res., 2000, 91: 886-892.; Okajima E, Denda A, Ozono S et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-4-hydroxybutyl)nitrosa-mine. Cancer Res., 1998, 58: 3028-3031.; https://www.med-sovet.pro/jour/article/view/459

الاتاحة: https://www.med-sovet.pro/jour/article/view/459
https://doi.org/10.21518/2079-701X-2015-18-84-89

المؤلفون: OD Ostroumova, ML Maksimov, OV Dralova, AS Yermolayeva, О. Остроумова Д., М. Максимов Л., О. Дралова В., А. Ермолаева С.

المصدر: Meditsinskiy sovet = Medical Council; № 12 (2014); 86-91 ; Медицинский Совет; № 12 (2014); 86-91 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2014-12

مصطلحات موضوعية: артериальная гипертензия, сердечная недостаточность, ингибиторы АПФ, фозиноприл, hypertension, heart failure, ACE inhibitors, fosinopril

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/693/693; Клиническая фармакология. Под ред. В.Г. Кукеса, 4-е изд. М.: «ГЭОТАР-Медиа», 2008: 392-395.; Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии, 2010, 3: 5-26.; Моисеев В.С., Кобалава ЖД. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин фармак. тер., 2002, 11(3): 16-18.; Мухин Н.А., Моисеев В.С., Кобалава ЖД. [и др.]. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер. архив, 2004, 6: 39-46.; Мухин Н.А. Снижение скорости клубочковой фильтрации - общепопуляционный маркер неблагоприятного прогноза. Тер. архив, 2007, 6: 5-10.; Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension, 2003, 42: 1050-1065.; Vetter W. Treatment of senile hypertension: the Fosinopril in Old Patients Study (FOPS). Am J Hypertens, 1997, 10 (10 Pt 2): 255-261.; Карпов Ю.А., Мареев В.Ю., Чазова И.Е. Российские программы оценки эффективности лечения фозиноприлом больных с артериальной гипертонией и сердечной недостаточностью. Проект Три Ф (ФЛАГ, ФАСОН, ФАГоТ). Сердечная недостаточность, 2003, 4 (5): 2-6.; O'Grady P, Yee KF, Lins R, Mangold B. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. Brit. J. Clin. Pharmacology, 1999, 48: 375-381.; Olivier PB, Germain ML, Carette BD et al. Elevation of serum creatinine following fosinopril therapy Ann. Pharmacother, 1999, 33: 382-383.; Карпов Ю.А. Фозиноприл при лечении артериальной гипертонии (ФЛАГ): российская программа оценки практической достижимости целевых уровней артериального давления. РЫЖ, 2001, 9. (10): 406-410.; Чазова И.Е. Первые результаты исследования ФАГОТ. Consihum Medicum, 2002, 4 (11): 596-598.; Мареев В.Ю. Фармакоэкономическая оценка использования ингибиторов АПФ в амбулаторном лечении больных с сердечной недостаточностью («ФАСОН»). Сердечная недостаточность, 2002, 3, 1: 38-39.; Рекомендации европейского общества кардиологов (ЕОК) по диагностике и лечению острой и хронической сердечной недостаточности 2012 года. Российский кардиологический журнал, 2012, 4 (102), 3: 20-22.; https://www.med-sovet.pro/jour/article/view/693

الاتاحة: https://www.med-sovet.pro/jour/article/view/693
https://doi.org/10.21518/2079-701X-2014-12-86-91